WO1997039797A1 - Method of treating movement disorders by brain stimulation and drug infusion - Google Patents
Method of treating movement disorders by brain stimulation and drug infusion Download PDFInfo
- Publication number
- WO1997039797A1 WO1997039797A1 PCT/US1997/005522 US9705522W WO9739797A1 WO 1997039797 A1 WO1997039797 A1 WO 1997039797A1 US 9705522 W US9705522 W US 9705522W WO 9739797 A1 WO9739797 A1 WO 9739797A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stimulation
- neural tissue
- neurotransmitter
- neural
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36067—Movement disorders, e.g. tremor or Parkinson disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
Definitions
- This invention relates to neural tissue stimulation and infusion techniques, and more particularly relates to such techniques for treating various disorders, including movement disorders.
- Patients with neurodegenerative diseases or trauma like cerebral infarct or spinal cord injury can have a variety of movement and muscle control problems, like resting, postural, intention or action tremor; dystonia (improper muscle tone); spasticity (undesirable movements, or muscle co-contraction); dyskinesia (poorly executed movements) or involuntary movements like ballismus, choreiform movements and torticollis (inappropriate movements or limb control).
- dyskinesia poorly executed movements
- involuntary movements like ballismus, choreiform movements and torticollis (inappropriate movements or limb control).
- hyperkinesia Although they can be chronic, or worse, progressive, they also may have times of relative remission.
- Dyskinesia also may result from long term usage of levodopa or other drugs, especially for Parkinson's patients.
- Spasticity is defined as a state of excessive muscular tonus (hypertonus) and increased spinal reflexes. This condition exists when the corticospinal pathways have been disrupted. Disruption can occur as a result of stroke causing injury to the fibers as they pass through the internal capsule, a degenerative disorder or physical trauma to the cortex or spinal cord. Loss of this pathway leads to a lack of inhibition of the lower motorneurons which then are more active and responsive to reflexes. In some cases injury to the premotor cortex disrupts the output of the primary motor cortex leading to the similar phenomena.
- One form of the Dyskinesia is known as Ballism which typically results in violent flinging movements of the limbs. The movements often affect only one side of the body, in which case the disorder is known as Hemiballism.
- Tremor In patients suffering essential tremor or tremor due to Parkinson's Disease, the predominant symptom of the disordered movement is tremor. Tremor is often subdivided on the basis of whether the trembling of the limb occurs when the limb is at rest or when muscular contraction is occurring. Besides being caused by degenerative illness or head injury, tremor can be of unknown origin. One syndrome of idopathic tremor is referred to as essential tremor.
- Patients with neurodegenerative diseases or trauma to the basal ganglia like cerebral infarct can have a variety of movement and muscle control problems, like akinesia (impairment in movement initiation), rigidity (stiffness, inflexibility, immobility) or bradykinesia (reduction in amplitude and velocity of movement).
- akinesia impairment in movement initiation
- rigidity stiffness, inflexibility, immobility
- bradykinesia reduction in amplitude and velocity of movement.
- These motor disorders may be classified as hypokinetic problems, reflecting an abnormal reduction in voluntary movement.
- These problems can be chronic, or worse, progressive, but they also may have times of relative remission, especially when drugs are effective.
- Dyskinesia is often a side-effect from medications used for certain symptoms (like tremor, akinesia, rigidity), especially levodopa.
- DBS Deep Brain Stimulation
- Hz. or higher of certain brain structures can alleviate, diminish, or completely stop symptoms of tremor, rigidity, akinesia or hemiballism.
- Published targets of stimulation include the VIM (ventral intermediate thalamus). subthalamic nucleus, and internal globus pallidus. It is believed that many symptoms of the foregoing motion disorders are due to dysfunction of the basal ganglia or thalamus. The dysfunction can result in overactivity of the output neurons of the ganglia creating excessive inhibition of the thalamus or underactivity of the ganglia resulting in too little inhibition of the thalamus.
- a preferred form of the invention uses one or more drugs and electrical stimulation to treat a neural disorder.
- the treatment is carried out by an implantable pump and a catheter having a proximal end coupled to the pump and having a discharge portion for infusing therapeutic dosages of the one or more drugs into a predetermined infusion site in neural tissue.
- the treatment also is carried out by an implantable signal generator and an implantable electrode having a proximal end coupled to the signal generator and having a stimulation portion for electrically stimulating a predetermined stimulation site in the neural tissue.
- the symptoms of hypokinetic disorders such as Parkinson's disease, Akinesia, Bradykinesia or Rigidity
- hyperkinetic disorders such as Ballism, Hemiballism, Chorea, Torticollis, Spasticity or Dystonia
- the stimulation and infusion can decrease excitement of the thalamus or increase inhibition of the thalamus.
- the stimulation and infusion can increase excitement of the thalamus or decrease inhibition of the thalamus.
- Another form of ie invention uses a sensor in combination with the signal generator, stimulating e ctrode, pump and catheter to treat a neural disorder.
- a sensor generates a sensor signal related to activity resulting from said neural disordu .
- Control means responsive to the sensor signal regulate the signal generator and pump so that the neural disorder is treated.
- Figure 1 is a diagrammatic illustration of a combined catheter and electrode implanted in a brain according to a preferred embodiment of the present invention, and a signal generator and pump coupled to the combined catheter and electrode;
- Figure 2 is a diagrammatic illustration of a portion of the nervous system of the human body in which a preferred form of motion sensor, signal generator, pump and combined catheter and electrode have been implanted;
- Figure 3 is a schematic block diagram of a sensor and analog to digital converter circuit used in the preferred embodiment of the invention
- Figure 4 is a flow chart illustrating a preferred form of a microprocessor program for utilizing the sensor to control drug dosage administered to the brain;
- Figure 5 is a schematic block diagram of a microprocessor and related circuitry for utilizing the sensor to control stimulation administered to the brain;
- Figures 6-10 are flow charts illustrating a preferred form of microprocessor program for generating stimulation pulses to be administered to the brain
- Figure 11 is a cross sectional view of the catheter-electrode taken along line 1 1-1 1 of Figure 12;
- Figures 12-17 are diagrammatical views of the catheter-electrode shown in Figure 1 arranged adjacent various types of neural tissue; and Figures 18 A-l 8C are timing diagrams showing the relationship between the administration of drugs and electrical stimulation to neural tissue.
- a system or device 10 made in accordance with the preferred embodiment may be implanted below the skin of a patient.
- the device has a port 14 into which a hypodermic needle can be inserted tlirough the skin to inject a quantity of a liquid agent, such as a medication or drug.
- the liquid agent is delivered from device 10 through a catheter port 20 into a catheter 22.
- Catheter 22 is positioned to deliver the agent to specific infusion sites in a brain (B).
- Device 10 may take the form of the like-numbered device shown in U.S. Patent No. 4,692,147 (Duggan), assigned to Medtronic, Inc., Minneapolis, Minnesota, which is inco ⁇ orated by reference.
- catheter 22 terminates in a cylindrical hollow tube 22A having a distal end 25 implanted into a portion of the basal ganglia of the brain by conventional stereotactic surgical techniques.
- End 25 is provided with microporous portions 27-29 in the preferred embodiment ( Figure 12); however, multiple holes or slits within portions 27-29 could also be used. Additional details about portions 27-29 may be obtained from pending U.S. Application Serial No. 08/430,960 entitled "Intraparenchymal Infusion Catheter System," filed April 28, 1995, in the name of Dennis Elsberry et al. and assigned to the same assignee as the present application.
- tube 22A includes an outer cylindrical insulating jacket 30 and an inner cylindrical insulating jacket 32 that defines a cylindrical catheter lumen 34.
- a multifilar coil or strands of wire 36 is embedded in tube 22A as shown.
- Tube 22A is surgically implanted through a hole in the skull 123 and catheter 22 is implanted between the skull and the scalp 125 as shown in Figure 1.
- a stylet may be placed into the center of tube 22A to give it stiffness when introducing the tube into the brain or other neural tissue.
- center lumen 34 constitutes a catheter which can be used to infuse an agent, including a drug.
- Catheter 22 is joined to implanted device 10 in the manner shown.
- device 10 is implanted in a human body 120 in the location shown.
- Body 120 includes arms 122 and 123.
- device 10 may be implanted in the abdomen.
- Catheter 22 may be divided into twin tubes 22A and 22B that are implanted into the brain bilaterally as shown.
- tube 22B may be supplied with drugs from a separate catheter and pump.
- a system or device 16 made in accordance with the preferred embodiment also may be implanted below the skin of a patient.
- Device 16 may take the form of a signal generator Model 7424 manufactured by Medtronic, Inc. under the trademark Itrel II which is incorporated by reference.
- the distal end of tube 22 A terminates in stimulation electrodes 38 and 40
- Electrodes 38 and 40 are individually connected to device 16 through a conductor in wire 36 ( Figure 1 1 ).
- device 16 is implanted in a human body 120 in the location shown. Alternatively, device 16 may be implanted elsewhere, such as in the abdomen.
- a sensor 130 is implanted into a portion of a patient's body suitable for detecting symptoms of the motion disorder being treated.
- Sensor 130 is adapted to sense an attribute of the symptom to be controlled or an important related symptom.
- sensor 130 may be a motion detector implanted in arm 122 as shown.
- sensor 130 may sense three-dimensional or two-dimensional motion (linear rotational or joint motion), such as by an accelerometer.
- One such sensor suitable for use with the present invention is described in U.S. Patent No. 5,293,879 (Vonk et al.).
- Another suitable accelerometer is found in pacemakers manufactured by Medtronic, Inc. and described in Patent Application Serial No. 08/399072 entitled "Package Integrated Accelerometer", filed March 8, 1995, in the names of James Sikorski and Larry R. Larson.
- Sensor 130 also may be placed in device 10 in order to detect abnormal movement resulting from the motion disorder being treated.
- Sensor 130 also may be capable of detecting gravity direction or motion relative to some object (e.g., a magnet) either implanted or fixed nearby. Sensor 130 also may take the form of a device capable of detecting force in muscles or at joints, or pressure. W
- Sensor 130 may detect muscle EMG in one, two or more muscles, or in reciprocal muscles at one joint. For such detection, sensor 130 may take the form of a lead with one or more recording electrodes inserted into the muscle of interest.
- Brain EEG (e.g., motor cortex potentials recorded above the motor neurons controlling specific muscle groups) also may be detected by sensor 130.
- sensor 130 would include a device capable of detecting nerve compound action potentials (e.g., either sensory afferent information from muscle or skin receptors or efferent motor potentials controlling a muscle of interest).
- nerve compound action potentials e.g., either sensory afferent information from muscle or skin receptors or efferent motor potentials controlling a muscle of interest.
- sensor 130 may take the form of a device detecting the posture of the patient, such as the device shown in U.S. Patent No.
- Sensor 130 also may take the form of a device capable of detecting nerve cell or axon activity that is related to the pathways at the cause of the symptom, or that reflects sensations which are elicited by the symptom.
- a sensor may be located deep in the brain.
- sensor 130 may take the form of an electrode inserted into the internal capsule, motor cortex or basal ganglia of the brain. Signals that are received by the sensor may by amplified before transmission to circuitry contained within device 10 or device 16.
- Sensor 130 may take the form of a transducer consisting of an electrode with an ion selective coating applied which is capable of directly transducing the amount of a particular transmitter substance or its breakdown by-products found in the interstitial space of a region of the brain such as the ventral lateral thalamus.
- the level of the interstitial transmitter substance is an indicator of the relative activity of the brain region.
- An example of this type of transducer is described in the paper "Multichannel semiconductor-based electrodes for in vivo electrochemical and electrophysiological studies in rat CNS" by Craig G. van Home, Spencer Bement, Barry J. Hoffer, and Greg A. Gerhardt, published in Neuroscience Letters, 120 (1990) 249-252.
- the relative motion of a joint or limb or muscle EMG may be productively sensed. Sensing electrical activity of neurons in various locations of the motor circuitry also is helpful. Recording the electrical activity in the thalamus will reveal a characteristic oscillating electrical activity when tremor is present.
- sensor 130 may take the form of an accelerometer detecting relative motion of a joint or limb or muscle EMG.
- sensor 130 may take the form of a device for detecting relative motion of a joint or limb or muscle EMG.
- the output of sensor 130 is coupled by a cable 132 comprising conductors 134 and 135 to the input of analog to digital converter 140.
- the output of an external feedback sensor would communicate with the implanted pulse generator through a telemetry downlink.
- the output of the analog to digital converter is connected to terminals EF2 BAR and EF3 BAR shown in Figure 1 IA of U.S. Patent No. 4,692,147 ("'147 Patent").
- the demodulator 101 currently shown in Figure 1 1 A would be disconnected.
- the present invention may be implemented by providing seven different drug dosages from 0 dosage to a 1.0 ml dosage with 0.1 ml increments between choices.
- the time interval between dosages can be selected between one and twelve hours in seven choices. This is the same type of dosage and interval described in connection with device 10 shown in the '147 Patent (column 5, beginning at line 63).
- the seven drug dosages and corresponding time increments may be loaded into RAM 102a
- Microprocessor 100 included within device 10 reads converter 140 in step 150, and stores one or more values in RAM 102a in step 152. One of seven dosages is selected in step 154, and an appropriate time interval is selected in step 156. The selected dosage and interval of a drug is then delivered through catheter 22 and tube 22 A to the basal ganglia of the brain as described in the ' 147 Patent. For some types of motion disorders, a microprocessor and analog to digital converter will not be necessary.
- the output from sensor 130 can be filtered by an appropriate electronic filter in order to provide a control signal for a pump of the type shown in the '147 Patent.
- the type of drugs administered by device 10 into the brain depend on the specific location at which distal end 25 of tube 22A is surgically implanted.
- the appropriate drugs for use in connection with the portion of the basal ganglia or thalamus in which tube 22A terminates, together with the effect of the drug on that portion of the brain for hyperkinetic motion disorders is provided in the following Table I:
- VL Thalamus means ventrolateral thalamus; GPi means internal segment of globus pallidus; SNr means substantia nigra pars reticulata, STN means subthalamic nucleus; neostriatum means the combination of the caudate nucleus and the putamen; and GPe means external segment of globus pallidus.
- the medial-lateral dimensions are relative to midline of the brain; the anterior-posterior dimensions are relative to the midpoint between the anterior commissure and posterior commissure with negative indicating the posterior direction; the dorsal -ventral dimensions are relative to a line connecting the midpoints of the anterior and posterior commissures with negative being ventral to; all dimensions are in centimeters.
- muM means micromolar
- a drug can be delivered essentially continuously (within the constraints of the particular delivery device being used) or it may be delivered during intermittent intervals coordinated to reflect the half-life of the particular agent being infused or circadian rhythms.
- the motor symptoms may normally subside at night when the person is sleeping so the drug delivery rates might be reduced to coincide with the hours between 10 p.m. and 7 a.m.
- Microprocessor 100 within device 10 can be programmed so that a controlled amount of drug can be delivered to the specific brain sites described in Table I.
- sensor 130 can be used with a closed loop feedback system in order to automatically determine the level of drug delivery necessary to alleviate motor disorder symptoms as described in connection with Figure 4.
- the applicants have discovered that the efficacy of treatment may be enhanced if the neural tissue is stimulated while drugs are being administered as described above.
- the stimulation can be achieved by a modified form of the ITREL II signal generator implemented as device 16 ( Figure 1) which is described in Figure 5.
- the output of sensor 130 is coupled by cable 132, comprising conductors 134 and 135, to the input of an analog to digital converter 206.
- the output of an external sensor would communicate with the implanted pulse generator through a telemetry downlink.
- the output of the analog to digital converter 206 is connected to a microprocessor 200 through a peripheral bus 202 including address, data and control lines.
- Microprocessor 200 processes the sensor data in different ways depending on the type of transducer in use. When the signal on sensor 130 exceeds a level programmed by the clinician and stored in a memory 204, increasing amounts of stimulation will be applied through an output driver 224.
- the stimulus pulse frequency is controlled by programming a value to a programmable frequency generator 208 using bus 202.
- the programmable frequency generator provides an interrupt signal to microprocessor 200 through an interrupt line 210 when each stimulus pulse is to be generated.
- the frequency generator may be implemented by model CDP1878 sold by Harris Corporation.
- the amplitude for each stimulus pulse is programmed to a digital to analog converter 218 using bus 202.
- the analog output is conveyed through a conductor 220 to an output driver circuit 224 to control stimulus amplitude.
- Microprocessor 200 also programs a pulse width control module 214 using bus
- the pulse width control provides an enabling pulse of duration equal to the pulse width via a conductor 216. Pulses with the selected characteristics are then delivered from device 16 through cable 22 and lead 22A to the basal ganglia, thalamus or other region of the brain.
- Microprocessor 200 executes an algorithm shown in Figures 6-10 in order to provide stimulation with closed loop feedback control.
- Step 400 in Figure 6 indicates the process of first choosing whether the neural activity at the stimulation site is to be blocked or facilitated (step 400(1)) and whether the sensor location is one for which an increase in the neural activity at that location is equivalent to an increase in neural activity at the stimulation target or vice versa (step 400(2)).
- the clinician must program the range of values for pulse width (step 400(3)), amplitude (step 400(4)) and frequency (step 400(5)) which device 10 may use to optimize the therapy.
- clinician may also choose the order in which the parameter changes are made (step 400(6)). Alternatively, the clinician may elect to use default values.
- the algorithm for selecting parameters is different depending on whether the clinician has chosen to block the neural activity at the stimulation target or facilitate the neural activity.
- Figure 6 details steps of the algorithm to make parameter changes.
- the algorithm uses the clinician programmed indication of whether the neurons at the particular location of the stimulating electrode are to be facilitated or blocked in order to reduce the neural activity in the subthalamic nucleus to decide which path of the parameter selection algorithm to follow (step 420, Figure 7). If the neuronal activity is to be blocked, device 16 first reads the feedback sensor 130 in step
- step 421 If the sensor values indicate the activity in the glutamatergic neurons is too high (step 422), the algorithm in this embodiment first increases the frequency of stimulation in step 424 provided this increase does not exceed the preset maximum value set by the physician. Step 423 checks for this condition. If the frequency parameter is not at the maximum, the algorithm returns to step 421 through path 421 A to monitor the feed back signal from sensor 130. If the frequency parameter is at the maximum, the algorithm next increases the pulse width in step 426 ( Figure 8), again with the restriction that this parameter has not exceeded the maximum value as checked for in step 425 through path 423A. Not having reached maximum pulse width, the algorithm returns to step 421 to monitor the feedback signal from sensor
- step 429 a notification message is set in step 429 to be sent by telemetry to the clinician indicating that device 16 is unable to reduce neural activity to the desired level.
- the algorithm would follow a different sequence of events.
- the frequency parameter would be fixed at a value chosen by the clinician to facilitate neuronal activity in step 430 ( Figure 9) through path 420A.
- the algorithm uses the values of the feedback sensor to determine if neuronal activity is being adequately controlled. In this case, inadequate control indicates that the neuronal activity of the stimulation target is too low.
- Neuronal activity is increased by first increasing stimulation amplitude (step 434) provided it doesn't exceed the programmed maximum value checked for in step 433.
- the algorithm increases pulse width to its maximum value in steps 435 and 436 ( Figure 10).
- the algorithm returns to step 431 through path 431 A, and the feedback sensor again is read.
- steps 410 through 415 constitute the method to do this.
- a timer is reset in step 415. If there is no need to change any stimulus parameters before the timer has counted out, then it may be possible due to changes in neuronal activity to reduce the parameter values and still maintain appropriate levels of neuronal activity in the target neurons.
- device 16 tries reducing a parameter in step 413 to determine if control is maintained. If it is.
- Electrodes 38 and 40 Figure 12
- Pulses with the selected characteristics are then delivered from device 16 through cable 42, catheter 22, tube 22A and electrodes 38 and 40 to the basal ganglia or thalamus of the brain.
- the output from sensor 130 can be filtered by an appropriate electronic filter in order to provide a control signal for device 16.
- the type of stimulation administered by device 16 to the brain depends on the specific location at which the electrodes 38 and 40 of tube 22A are surgically implanted.
- the appropriate stimulation for the portion of the basal ganglia or thalamus in which tube 22A terminates, together with the effect of the stimulation on that portion of the brain for hyperkinetic motion disorders is provided in the following Table V:
- VL Thalamus means ventrolateral thalamus; GPi means internal segment of globus pallidus; SNr means substantia nigra pars reticulata, STN means subthalamic nucleus; LT means the Lenticulo-thalamic fiber pathway; neostriatum means the combination of the caudate nucleus and the putamen; and GPe means external segment of globus pallidus.
- a microprocessor or custom integrated circuit within device 16 can be programmed so that the desired stimulation can be delivered to the specific brain sites described in Tables IV and V.
- sensor 130 can be used with a closed loop feedback system in order to automatically determine the type of stimulation necessary to alleviate motor disorder symptoms as described in connection with Figures 5-10.
- Figure 12 describes one such application in which type A neurons, such as NA, are located in the same region as type B neurons, such as NB.
- type A neurons such as NA
- type B neurons such as NB
- neurons NA can be inhibited or excited with respect to their response to electrical stimulation provided by electrodes 38 and 40, while neurons NB remain unchanged with respect to their response to such stimulation.
- neurons NA or NB can be selectively stimulated by electrodes 38 and 40 due to the infusion of substances through portions 27-29 of tube 22 A.
- a neuron NI has a cell body CB1 and a nucleus NU1.
- Neuron NI can be excited by axon terminals ATI at synapses SN1-SN2 by an inhibitory neurotransmitter TRB and can be excited by axon terminals AT2 at synapses SN4-SN6 by an excitatory neurotransmitter TRA.
- Portions 27-29 are used to infuse into the region of neuron NI one or more of the following agents: an antagonist of transmitter TRB, an agonist of transmitter TRA, an agent to block the reuptakc of transmitter TRA, a degradative enzyme for transmitter TRB and potassium.
- the agents can be infused separately or together in a cocktail.
- Such infusion leads to partial depolarization of neuron N 1 and to a reduced threshold to stimulation by electrodes 38 and 40. That is, after infusion, the amplitude of stimulation required to create action potentials in neuron NI is reduced compared to the time period before infusion.
- a neuron N2 has a cell body CB2 and a nucleus NU2.
- Neuron N2 can be inhibited by axon terminals AT3 at synapses SN7-SN8 by an inhibitory neurotransmitter TRB and can be excited by axon terminals AT4 at synapses SN10-SN12 by an excitatory neurotransmitter TRC.
- a neuron N3 has a cell body CB3 and a nucleus NU3.
- Neuron N3 can be inhibited by axon terminals AT5 at synapses SN 14-SN16 by an inhibitory neurotransmitter TRA.
- Portions 27-29 of tube 22A are used to infuse into the region of neurons N2 and N3 one or more of the following agents: an agonist of transmitter TRA, an agent to block the reuptake of transmitter TRA or an agent to block a degradative enzyme for transmitter TRA.
- an agonist of transmitter TRA an agent to block the reuptake of transmitter TRA
- an agent to block a degradative enzyme for transmitter TRA an agent to block a degradative enzyme for transmitter TRA.
- Each of these agents hyperpolarize neuron
- neuron N2 can be selectively activated by electrodes 38 and 40 so that an action potential is created in neuron N2 without creating an action potential in neuron N3.
- Selective activation of neuron N2 also can be achieved by infusing into the region of neurons N2 and N3 one or more of the following agents: an agonist for transmitter TRC, an agent to block the reuptake of transmitter TRC. an agent to block the degrading enzyme for transmitter TRC, an antagonist for transmitter TRB, an agent to enhance the reuptake of transmitter TRB or a degrading enzyme for transmitter TRB.
- the agents can be infused separately or together in a cocktail.
- neurons N4-N6 have cells bodies CB4-CB6, respectively, and axons A4-A6, respectively, which are long fibers of passage that typically pass through white tissue in the spinal cord or brain.
- Cell bodies CB4-CB6 are located at portions of the body somewhat remote from infusion portions 27-29 and electrodes 38 and 40.
- Neurons N7-N9 have cell bodies that are located in the region of infusion portions 27-29 and electrodes 38 and 40.
- Neuron N7 can be inhibited at axon terminals AT7 by an inhibitory neurotransmitter TRA and excited at axon terminals AT8 by an excitatory neurotransmitter TRB; neuron N9 can be inhibited at axon terminals AT9 by inhibitory neurotransmitter
- Neuron N8 can be inhibited at axon terminals ATI 1 by inhibitory neurotransmitter TRA and excited at axon terminals AT 12 by an excitatory neurotransmitter TRB.
- Portions 27-29 are used to infuse an agonist of transmitter TRA.
- Neurons N4-N6 are not affected by the infusion and can be selectively activated by stimulation supplied by electrodes 38 and 40.
- Figure 16 illustrates a modified form of tube 22 A in which infusion portion 27 is located more than 0.01 cm from electrodes 38 and 40 and infusion portions 28-29 have been removed.
- Neuron N10 has a cell body CB10 and an axon ⁇ 10 that terminates in axon terminals ATM.
- a neuron NI 1 can be excited at axon terminals ATM by an excitatory neurotransmitter TRA. Electrical stimulation of axon Al 0 causes the release of transmitter TRA at axon terminal ATM.
- Portion 27 is used to infuse an agent that blocks a degradative enzyme of transmitter TRA or an agent which blocks the reuptake of transmitter TRA. For each pulse administered by electrodes 38 and 40, the stimulation of neuron NI 1 is more potent. That is, more action potentials are generated in neuron Ni l .
- Figure 18A illustrates various times at which infusion and stimulation can be applied by tube 22A.
- infusion alone can be applied from time Tl to T2
- infusion and stimulation can be both be applied from time T2 to T3
- stimulation alone can be applied from time T3 to T4.
- This regimen might be used in the case when selective activation of one neuronal population is desired.
- the threshold for electrical activation of one population of neurons can be lowered or raised as needed.
- a precursor molecule such as L-dopa
- the stimulation might be applied periodically during the period of infusion either routinely or in response to sensor or patient generated demand as shown in figure 18B.
- the infusion of an agent to activate a neuronal population might be alternated with application of electrical stimulation of that same population, as shown in Figure 18C.
- Figure 17 illustrates the same form of tube 22A shown in Figure 16 implanted adjacent a spinal cord SC.
- a steroid, or other anti-inflammatory drug can be infused through portion 27 to reduce inflammation in area IN of the spinal cord, while portion ST, such as the dorsal columns, is electrically stimulated by electrodes 38 and 40 to treat the pain.
- an antispasmodic could be infused to treat the spasms associated with mechanical back problems while stimulation is applied to the spinal cord to treat the pain.
Abstract
Techniques using one or more drugs and electrical stimulation for treating neural disorders, including movement disorders resulting in abnormal motor response, by means of an implantable signal generator and electrode and an implantable pump and catheter. A sensor is used to detect activity resulting from the neural disorder. A microprocessor algorithm analyzes the output from the sensor in order to regulate the stimulation and drug dosage delivered to the neural tissue.
Description
METHOD OF TREATING MOVEMENT DISORDERS BY BRAIN STIMULATION AND DRUG INFUSION
BACKGROUND OF THE INVENTION Field of the Invention
This invention relates to neural tissue stimulation and infusion techniques, and more particularly relates to such techniques for treating various disorders, including movement disorders.
Description of Related Art Patients with neurodegenerative diseases or trauma like cerebral infarct or spinal cord injury can have a variety of movement and muscle control problems, like resting, postural, intention or action tremor; dystonia (improper muscle tone); spasticity (undesirable movements, or muscle co-contraction); dyskinesia (poorly executed movements) or involuntary movements like ballismus, choreiform movements and torticollis (inappropriate movements or limb control). Many of these problems can be called hyperkinesia. Although they can be chronic, or worse, progressive, they also may have times of relative remission. Such problems are found, at certain stages, for patients with Parkinson's disease, multiple sclerosis, cerebral palsy, secondary to deafferentation pain, post stroke, post apoplexy or anoxia, post head or spinal trauma, post poisoning, cerebellar disease, etc. Dyskinesia also may result from long term usage of levodopa or other drugs, especially for Parkinson's patients.
Spasticity is defined as a state of excessive muscular tonus (hypertonus) and increased spinal reflexes. This condition exists when the corticospinal pathways have been disrupted. Disruption can occur as a result of stroke causing injury to the fibers as they pass through the internal capsule, a degenerative disorder or physical trauma to the cortex or spinal cord. Loss of this pathway leads to a lack of inhibition of the lower motorneurons which then are more active and responsive to reflexes. In some cases injury to the premotor cortex disrupts the output of the primary motor cortex leading to the similar phenomena.
One form of the Dyskinesia is known as Ballism which typically results in violent flinging movements of the limbs. The movements often affect only one side of the body, in which case the disorder is known as Hemiballism.
In patients suffering essential tremor or tremor due to Parkinson's Disease, the predominant symptom of the disordered movement is tremor. Tremor is often subdivided on the basis of whether the trembling of the limb occurs when the limb is at rest or when muscular contraction is occurring. Besides being caused by degenerative illness or head injury, tremor can be of unknown origin. One syndrome of idopathic tremor is referred to as essential tremor. Patients with neurodegenerative diseases or trauma to the basal ganglia like cerebral infarct can have a variety of movement and muscle control problems, like akinesia (impairment in movement initiation), rigidity (stiffness, inflexibility, immobility) or bradykinesia (reduction in amplitude and velocity of movement). These motor disorders may be classified as hypokinetic problems, reflecting an abnormal reduction in voluntary movement. These problems can be chronic, or worse, progressive, but they also may have times of relative remission, especially when drugs are effective. Such problems are common, at certain stages, for patients with Parkinson's disease, multiple sclerosis, cerebral palsy, secondary to deafferentation pain, post stroke, post apoplexy or anoxia, post head or spinal trauma, post poisoning, cerebellar disease, etc. Dyskinesia is often a side-effect from medications used for certain symptoms (like tremor, akinesia, rigidity), especially levodopa.
Neurosurgeons have been able to diminish the symptoms of the foregoing movement disorders by lesioning certain brain areas. In addition, it has been demonstrated that open-loop Deep Brain Stimulation (DBS) at high frequencies (100
Hz. or higher) of certain brain structures can alleviate, diminish, or completely stop symptoms of tremor, rigidity, akinesia or hemiballism. Published targets of stimulation include the VIM (ventral intermediate thalamus). subthalamic nucleus, and internal globus pallidus.
It is believed that many symptoms of the foregoing motion disorders are due to dysfunction of the basal ganglia or thalamus. The dysfunction can result in overactivity of the output neurons of the ganglia creating excessive inhibition of the thalamus or underactivity of the ganglia resulting in too little inhibition of the thalamus. If there is too little output activity from the basal ganglia or too little inhibition of the thalamus, a condition such as Ballism or Dystonia will result. If there is too much output activity from the basal ganglia (too much inhibition), a condition such as Hypokinesia will result.
SUMMARY OF THE INVENTION A preferred form of the invention uses one or more drugs and electrical stimulation to treat a neural disorder. The treatment is carried out by an implantable pump and a catheter having a proximal end coupled to the pump and having a discharge portion for infusing therapeutic dosages of the one or more drugs into a predetermined infusion site in neural tissue. The treatment also is carried out by an implantable signal generator and an implantable electrode having a proximal end coupled to the signal generator and having a stimulation portion for electrically stimulating a predetermined stimulation site in the neural tissue.
By using the foregoing techniques, the symptoms of hypokinetic disorders, such as Parkinson's disease, Akinesia, Bradykinesia or Rigidity, and hyperkinetic disorders, such as Ballism, Hemiballism, Chorea, Torticollis, Spasticity or Dystonia can be alleviated. According to one embodiment of the invention, the stimulation and infusion can decrease excitement of the thalamus or increase inhibition of the thalamus. According to another embodiment of the invention, the stimulation and infusion can increase excitement of the thalamus or decrease inhibition of the thalamus.
Another form of ie invention uses a sensor in combination with the signal generator, stimulating e ctrode, pump and catheter to treat a neural disorder. In this form of the invention, . sensor generates a sensor signal related to activity resulting from said neural disordu . Control means responsive to the sensor signal regulate the signal generator and pump so that the neural disorder is treated.
By using the foregoing techniques, the symptoms of many neural disorders can be controlled to a degree unattainable by prior art methods or apparatus. BRIEF DESCRIPTION OF THE DRAWINGS
These and other advantages and features of the invention will become apparent upon reading the following detailed description and referring to the accompanying drawings in which like numbers refer to like parts throughout and in which:
Figure 1 is a diagrammatic illustration of a combined catheter and electrode implanted in a brain according to a preferred embodiment of the present invention, and a signal generator and pump coupled to the combined catheter and electrode; Figure 2 is a diagrammatic illustration of a portion of the nervous system of the human body in which a preferred form of motion sensor, signal generator, pump and combined catheter and electrode have been implanted;
Figure 3 is a schematic block diagram of a sensor and analog to digital converter circuit used in the preferred embodiment of the invention; Figure 4 is a flow chart illustrating a preferred form ofa microprocessor program for utilizing the sensor to control drug dosage administered to the brain;
Figure 5 is a schematic block diagram of a microprocessor and related circuitry for utilizing the sensor to control stimulation administered to the brain;
Figures 6-10 are flow charts illustrating a preferred form of microprocessor program for generating stimulation pulses to be administered to the brain;
Figure 11 is a cross sectional view of the catheter-electrode taken along line 1 1-1 1 of Figure 12;
Figures 12-17 are diagrammatical views of the catheter-electrode shown in Figure 1 arranged adjacent various types of neural tissue; and Figures 18 A-l 8C are timing diagrams showing the relationship between the administration of drugs and electrical stimulation to neural tissue.
DESCRIPTION OF THE PREFERRED EMBODIMENTS Referring to Figure 1, a system or device 10 made in accordance with the preferred embodiment may be implanted below the skin of a patient. The device has a port 14 into which a hypodermic needle can be inserted tlirough the skin to inject a
quantity of a liquid agent, such as a medication or drug. The liquid agent is delivered from device 10 through a catheter port 20 into a catheter 22. Catheter 22 is positioned to deliver the agent to specific infusion sites in a brain (B). Device 10 may take the form of the like-numbered device shown in U.S. Patent No. 4,692,147 (Duggan), assigned to Medtronic, Inc., Minneapolis, Minnesota, which is incoφorated by reference.
The distal end of catheter 22 terminates in a cylindrical hollow tube 22A having a distal end 25 implanted into a portion of the basal ganglia of the brain by conventional stereotactic surgical techniques. End 25 is provided with microporous portions 27-29 in the preferred embodiment (Figure 12); however, multiple holes or slits within portions 27-29 could also be used. Additional details about portions 27-29 may be obtained from pending U.S. Application Serial No. 08/430,960 entitled "Intraparenchymal Infusion Catheter System," filed April 28, 1995, in the name of Dennis Elsberry et al. and assigned to the same assignee as the present application. Referring to Figure 11 , tube 22A includes an outer cylindrical insulating jacket 30 and an inner cylindrical insulating jacket 32 that defines a cylindrical catheter lumen 34. A multifilar coil or strands of wire 36 is embedded in tube 22A as shown.
Tube 22A is surgically implanted through a hole in the skull 123 and catheter 22 is implanted between the skull and the scalp 125 as shown in Figure 1. A stylet may be placed into the center of tube 22A to give it stiffness when introducing the tube into the brain or other neural tissue. After the stylet is removed, center lumen 34 constitutes a catheter which can be used to infuse an agent, including a drug. Catheter 22 is joined to implanted device 10 in the manner shown.
Referring to Figure 2, device 10 is implanted in a human body 120 in the location shown. Body 120 includes arms 122 and 123. Alternatively, device 10 may be implanted in the abdomen.
Catheter 22 may be divided into twin tubes 22A and 22B that are implanted into the brain bilaterally as shown. Alternatively, tube 22B may be supplied with drugs from a separate catheter and pump.
Referring again to Figure 1 , a system or device 16 made in accordance with the preferred embodiment also may be implanted below the skin of a patient. Device 16 may take the form ofa signal generator Model 7424 manufactured by Medtronic, Inc. under the trademark Itrel II which is incorporated by reference. The distal end of tube 22 A terminates in stimulation electrodes 38 and 40
(Figure 12). Each of electrodes 38 and 40 is individually connected to device 16 through a conductor in wire 36 (Figure 1 1 ). The w ires exit catheter 22 to form a cable 42 which is joined to implanted device 16 in the manner shown in Figure 1. While the preferred embodiment shows two electrodes on tube 22 A (Figure 12), some applications may require a greater number.
Referring to Figure 2, device 16 is implanted in a human body 120 in the location shown. Alternatively, device 16 may be implanted elsewhere, such as in the abdomen.
A sensor 130 is implanted into a portion of a patient's body suitable for detecting symptoms of the motion disorder being treated. Sensor 130 is adapted to sense an attribute of the symptom to be controlled or an important related symptom. For motion disorders that result in abnormal movement of an arm, such as arm 122, sensor 130 may be a motion detector implanted in arm 122 as shown. For example, sensor 130 may sense three-dimensional or two-dimensional motion (linear rotational or joint motion), such as by an accelerometer. One such sensor suitable for use with the present invention is described in U.S. Patent No. 5,293,879 (Vonk et al.). Another suitable accelerometer is found in pacemakers manufactured by Medtronic, Inc. and described in Patent Application Serial No. 08/399072 entitled "Package Integrated Accelerometer", filed March 8, 1995, in the names of James Sikorski and Larry R. Larson. Sensor 130 also may be placed in device 10 in order to detect abnormal movement resulting from the motion disorder being treated.
Sensor 130 also may be capable of detecting gravity direction or motion relative to some object (e.g., a magnet) either implanted or fixed nearby. Sensor 130 also may take the form of a device capable of detecting force in muscles or at joints, or pressure.
W
Sensor 130 may detect muscle EMG in one, two or more muscles, or in reciprocal muscles at one joint. For such detection, sensor 130 may take the form of a lead with one or more recording electrodes inserted into the muscle of interest.
Brain EEG (e.g., motor cortex potentials recorded above the motor neurons controlling specific muscle groups) also may be detected by sensor 130.
Yet another form of sensor 130 would include a device capable of detecting nerve compound action potentials (e.g., either sensory afferent information from muscle or skin receptors or efferent motor potentials controlling a muscle of interest).
For certain types of patients, sensor 130 may take the form of a device detecting the posture of the patient, such as the device shown in U.S. Patent No.
5,031 ,618 (Mullett).
Sensor 130 also may take the form of a device capable of detecting nerve cell or axon activity that is related to the pathways at the cause of the symptom, or that reflects sensations which are elicited by the symptom. Such a sensor may be located deep in the brain. For such detecting, sensor 130 may take the form of an electrode inserted into the internal capsule, motor cortex or basal ganglia of the brain. Signals that are received by the sensor may by amplified before transmission to circuitry contained within device 10 or device 16.
Sensor 130 may take the form of a transducer consisting of an electrode with an ion selective coating applied which is capable of directly transducing the amount of a particular transmitter substance or its breakdown by-products found in the interstitial space of a region of the brain such as the ventral lateral thalamus. The level of the interstitial transmitter substance is an indicator of the relative activity of the brain region. An example of this type of transducer is described in the paper "Multichannel semiconductor-based electrodes for in vivo electrochemical and electrophysiological studies in rat CNS" by Craig G. van Home, Spencer Bement, Barry J. Hoffer, and Greg A. Gerhardt, published in Neuroscience Letters, 120 (1990) 249-252.
For tremor, the relative motion of a joint or limb or muscle EMG may be productively sensed. Sensing electrical activity of neurons in various locations of the
motor circuitry also is helpful. Recording the electrical activity in the thalamus will reveal a characteristic oscillating electrical activity when tremor is present.
For Ballism, Hemiballism or tremor, sensor 130 may take the form of an accelerometer detecting relative motion of a joint or limb or muscle EMG. For Dystonia, sensor 130 may take the form of a device for detecting relative motion of a joint or limb or muscle EMG.
Referring to Figure 3, the output of sensor 130 is coupled by a cable 132 comprising conductors 134 and 135 to the input of analog to digital converter 140. Alternatively, the output of an external feedback sensor would communicate with the implanted pulse generator through a telemetry downlink. The output of the analog to digital converter is connected to terminals EF2 BAR and EF3 BAR shown in Figure 1 IA of U.S. Patent No. 4,692,147 ("'147 Patent"). Before converter 140 is connected to the terminals, the demodulator 101 currently shown in Figure 1 1 A would be disconnected. The present invention may be implemented by providing seven different drug dosages from 0 dosage to a 1.0 ml dosage with 0.1 ml increments between choices. The time interval between dosages can be selected between one and twelve hours in seven choices. This is the same type of dosage and interval described in connection with device 10 shown in the '147 Patent (column 5, beginning at line 63). The seven drug dosages and corresponding time increments may be loaded into RAM 102a
(Figure 1 IB) of the '147 Patent. The appropriate drug dosage and interval is selected by a computer algorithm that reads the output of converter 140 and makes the appropriate selection.
One exemplary computer algorithm is shown in Figure 4. Microprocessor 100 included within device 10 reads converter 140 in step 150, and stores one or more values in RAM 102a in step 152. One of seven dosages is selected in step 154, and an appropriate time interval is selected in step 156. The selected dosage and interval of a drug is then delivered through catheter 22 and tube 22 A to the basal ganglia of the brain as described in the ' 147 Patent.
For some types of motion disorders, a microprocessor and analog to digital converter will not be necessary. The output from sensor 130 can be filtered by an appropriate electronic filter in order to provide a control signal for a pump of the type shown in the '147 Patent.
The type of drugs administered by device 10 into the brain depend on the specific location at which distal end 25 of tube 22A is surgically implanted. The appropriate drugs for use in connection with the portion of the basal ganglia or thalamus in which tube 22A terminates, together with the effect of the drug on that portion of the brain for hyperkinetic motion disorders is provided in the following Table I:
TABLE I
The appropriate drugs for use in connection with the portion of the basal ganglia or thalamus in which tube 22 A terminates, together with the effect of the drug on that portion of the brain for hypokinetic motion disorders is provided in the following Table II:
TABLE II
In the foregoing Tables I and II, VL Thalamus means ventrolateral thalamus; GPi means internal segment of globus pallidus; SNr means substantia nigra pars reticulata, STN means subthalamic nucleus; neostriatum means the combination of the caudate nucleus and the putamen; and GPe means external segment of globus pallidus.
Typical stereotaxic coordinates for the portions of a normal brain described in Tables I and II are identified in the following Table III:
TABLE III
In the foregoing table: the medial-lateral dimensions are relative to midline of the brain; the anterior-posterior dimensions are relative to the midpoint between the anterior commissure and posterior commissure with negative indicating the posterior direction; the dorsal -ventral dimensions are relative to a line connecting the midpoints of the anterior and posterior commissures with negative being ventral to; all dimensions are in centimeters.
Exemplary ranges of dosages and drug concentrations for the drugs identified in Tables I and II are provided in the following Table IV:
TABLE IV
In the preceding table, muM means micromolar.
A drug can be delivered essentially continuously (within the constraints of the particular delivery device being used) or it may be delivered during intermittent intervals coordinated to reflect the half-life of the particular agent being infused or circadian rhythms. As an example, the motor symptoms may normally subside at night when the person is sleeping so the drug delivery rates might be reduced to coincide with the hours between 10 p.m. and 7 a.m.
Microprocessor 100 within device 10 can be programmed so that a controlled amount of drug can be delivered to the specific brain sites described in Table I. Alternatively, sensor 130 can be used with a closed loop feedback system in order to automatically determine the level of drug delivery necessary to alleviate motor disorder symptoms as described in connection with Figure 4. The applicants have discovered that the efficacy of treatment may be enhanced if the neural tissue is stimulated while drugs are being administered as described above. The stimulation can be achieved by a modified form of the ITREL II signal generator implemented as device 16 (Figure 1) which is described in Figure 5. The output of sensor 130 is coupled by cable 132, comprising conductors 134 and 135, to the input of an analog to digital converter 206. Alternatively, the output of an external sensor would communicate with the implanted pulse generator through a telemetry downlink.
The output of the analog to digital converter 206 is connected to a microprocessor 200 through a peripheral bus 202 including address, data and control lines. Microprocessor 200 processes the sensor data in different ways depending on the type of transducer in use. When the signal on sensor 130 exceeds a level programmed by the clinician and stored in a memory 204, increasing amounts of stimulation will be applied through an output driver 224.
The stimulus pulse frequency is controlled by programming a value to a programmable frequency generator 208 using bus 202. The programmable frequency generator provides an interrupt signal to microprocessor 200 through an interrupt line 210 when each stimulus pulse is to be generated. The frequency generator may be implemented by model CDP1878 sold by Harris Corporation.
The amplitude for each stimulus pulse is programmed to a digital to analog converter 218 using bus 202. The analog output is conveyed through a conductor 220 to an output driver circuit 224 to control stimulus amplitude. Microprocessor 200 also programs a pulse width control module 214 using bus
202. The pulse width control provides an enabling pulse of duration equal to the pulse width via a conductor 216. Pulses with the selected characteristics are then delivered from device 16 through cable 22 and lead 22A to the basal ganglia, thalamus or other region of the brain. Microprocessor 200 executes an algorithm shown in Figures 6-10 in order to provide stimulation with closed loop feedback control.
At the time the stimulation device 16 is implanted, the clinician programs certain key parameters into the memory of the implanted device via telemetry. These parameters may be updated subsequently as needed. Step 400 in Figure 6 indicates the process of first choosing whether the neural activity at the stimulation site is to be blocked or facilitated (step 400(1)) and whether the sensor location is one for which an increase in the neural activity at that location is equivalent to an increase in neural activity at the stimulation target or vice versa (step 400(2)). Next the clinician must program the range of values for pulse width (step 400(3)), amplitude (step 400(4)) and frequency (step 400(5)) which device 10 may use to optimize the therapy. The
7/39797 PC17US97/05522
16
clinician may also choose the order in which the parameter changes are made (step 400(6)). Alternatively, the clinician may elect to use default values.
The algorithm for selecting parameters is different depending on whether the clinician has chosen to block the neural activity at the stimulation target or facilitate the neural activity. Figure 6 details steps of the algorithm to make parameter changes.
The algorithm uses the clinician programmed indication of whether the neurons at the particular location of the stimulating electrode are to be facilitated or blocked in order to reduce the neural activity in the subthalamic nucleus to decide which path of the parameter selection algorithm to follow (step 420, Figure 7). If the neuronal activity is to be blocked, device 16 first reads the feedback sensor 130 in step
421. If the sensor values indicate the activity in the glutamatergic neurons is too high (step 422), the algorithm in this embodiment first increases the frequency of stimulation in step 424 provided this increase does not exceed the preset maximum value set by the physician. Step 423 checks for this condition. If the frequency parameter is not at the maximum, the algorithm returns to step 421 through path 421 A to monitor the feed back signal from sensor 130. If the frequency parameter is at the maximum, the algorithm next increases the pulse width in step 426 (Figure 8), again with the restriction that this parameter has not exceeded the maximum value as checked for in step 425 through path 423A. Not having reached maximum pulse width, the algorithm returns to step 421 to monitor the feedback signal from sensor
130. Should the maximum pulse width have been reached, the algorithm next increases amplitude in a like manner as shown in steps 427 and 428. In the event that all parameters reach the maximum, a notification message is set in step 429 to be sent by telemetry to the clinician indicating that device 16 is unable to reduce neural activity to the desired level.
If, on the other hand, the stimulation electrode is placed in a location which the clinician would like to activate in order to increase an inhibition of the subthalamic nucleus, the algorithm would follow a different sequence of events. In the preferred embodiment, the frequency parameter would be fixed at a value chosen by the clinician to facilitate neuronal activity in step 430 (Figure 9) through path 420A. In
steps 431 and 432 the algorithm uses the values of the feedback sensor to determine if neuronal activity is being adequately controlled. In this case, inadequate control indicates that the neuronal activity of the stimulation target is too low. Neuronal activity is increased by first increasing stimulation amplitude (step 434) provided it doesn't exceed the programmed maximum value checked for in step 433. When maximum amplitude is reached, the algorithm increases pulse width to its maximum value in steps 435 and 436 (Figure 10). A lack of adequate reduction of neuronal activity in the subthalamic nucleus, even though maximum parameters are used, is indicated to the clinician in step 437. After steps 434, 436 and 437, the algorithm returns to step 431 through path 431 A, and the feedback sensor again is read.
It is desirable to reduce parameter values to the minimum level needed to establish the appropriate level of neuronal activity in, for example, the subthalamic nucleus. Superimposed on the algorithm just described is an additional algorithm to readjust all the parameter levels downward as far as possible. In Figure 6, steps 410 through 415 constitute the method to do this. When parameters are changed, a timer is reset in step 415. If there is no need to change any stimulus parameters before the timer has counted out, then it may be possible due to changes in neuronal activity to reduce the parameter values and still maintain appropriate levels of neuronal activity in the target neurons. At the end of the programmed time interval, device 16 tries reducing a parameter in step 413 to determine if control is maintained. If it is. the various parameter values will be ratcheted down until such time as the sensor values again indicate a need to increase them. While the algorithms in Figure 6 follow the order of parameter selection indicated, other sequences may be programmed by the clinician. Electrical stimulation of neural tissue may be implemented by providing pulses to electrodes 38 and 40 (Figure 12) having amplitudes of 0.1 to 20 volts, pulse widths varying from 0.02 to 1.5 milliseconds, and repetition rates varying from 2 to 2500 Hz. The appropriate stimulation pulses are generated by device 16 based on the computer algorithm illustrated in Figures 6-10. Pulses with the selected
characteristics are then delivered from device 16 through cable 42, catheter 22, tube 22A and electrodes 38 and 40 to the basal ganglia or thalamus of the brain.
For some types of motion disorders, a microprocessor and analog to digital converter will not be necessary. The output from sensor 130 can be filtered by an appropriate electronic filter in order to provide a control signal for device 16.
The type of stimulation administered by device 16 to the brain depends on the specific location at which the electrodes 38 and 40 of tube 22A are surgically implanted. The appropriate stimulation for the portion of the basal ganglia or thalamus in which tube 22A terminates, together with the effect of the stimulation on that portion of the brain for hyperkinetic motion disorders is provided in the following Table V:
TABLE V
The appropriate stimulation for use in connection with the portion of the basal ganglia or thalamus in which tube 22A terminates, together with the effect of the stimulation on that portion of the brain for hypokinetic motion disorders is provided in the following Table VI:
TABLE VI
In the foregoing Tables V and VI, VL Thalamus means ventrolateral thalamus; GPi means internal segment of globus pallidus; SNr means substantia nigra pars reticulata, STN means subthalamic nucleus; LT means the Lenticulo-thalamic fiber pathway; neostriatum means the combination of the caudate nucleus and the putamen; and GPe means external segment of globus pallidus.
Coordinates for the portions of the brain described in Tables IV and V are the same as described in connection with Table III.
A microprocessor or custom integrated circuit within device 16 can be programmed so that the desired stimulation can be delivered to the specific brain sites described in Tables IV and V. Alternatively, sensor 130 can be used with a closed loop feedback system in order to automatically determine the type of stimulation necessary to alleviate motor disorder symptoms as described in connection with Figures 5-10.
The foregoing techniques for simultaneous drug infusion and electrical stimulation can be applied to neural tissue in general, and is not limited to the previously described locations in the brain. Figure 12 describes one such application in which type A neurons, such as NA, are located in the same region as type B neurons, such as NB. By infusing various agents through portions 27-29, neurons NA can be inhibited or excited with respect to their response to electrical stimulation provided by electrodes 38 and 40, while neurons NB remain unchanged with respect to their response to such stimulation. Thus, neurons NA or NB can be selectively stimulated by electrodes 38 and 40 due to the infusion of substances through portions 27-29 of tube 22 A.
Referring to Figure 13, a neuron NI has a cell body CB1 and a nucleus NU1. Neuron NI can be excited by axon terminals ATI at synapses SN1-SN2 by an inhibitory neurotransmitter TRB and can be excited by axon terminals AT2 at synapses SN4-SN6 by an excitatory neurotransmitter TRA. Portions 27-29 are used to infuse into the region of neuron NI one or more of the following agents: an antagonist of transmitter TRB, an agonist of transmitter TRA, an agent to block the reuptakc of transmitter TRA, a degradative enzyme for transmitter TRB and
potassium. The agents can be infused separately or together in a cocktail. Such infusion leads to partial depolarization of neuron N 1 and to a reduced threshold to stimulation by electrodes 38 and 40. That is, after infusion, the amplitude of stimulation required to create action potentials in neuron NI is reduced compared to the time period before infusion.
Referring to Figure 14, a neuron N2 has a cell body CB2 and a nucleus NU2. Neuron N2 can be inhibited by axon terminals AT3 at synapses SN7-SN8 by an inhibitory neurotransmitter TRB and can be excited by axon terminals AT4 at synapses SN10-SN12 by an excitatory neurotransmitter TRC. A neuron N3 has a cell body CB3 and a nucleus NU3. Neuron N3 can be inhibited by axon terminals AT5 at synapses SN 14-SN16 by an inhibitory neurotransmitter TRA. Portions 27-29 of tube 22A are used to infuse into the region of neurons N2 and N3 one or more of the following agents: an agonist of transmitter TRA, an agent to block the reuptake of transmitter TRA or an agent to block a degradative enzyme for transmitter TRA. Each of these agents hyperpolarize neuron
N3 and increase the potential threshold required to create action potentials in neuron N3. Therefore, neuron N2 can be selectively activated by electrodes 38 and 40 so that an action potential is created in neuron N2 without creating an action potential in neuron N3. Selective activation of neuron N2 also can be achieved by infusing into the region of neurons N2 and N3 one or more of the following agents: an agonist for transmitter TRC, an agent to block the reuptake of transmitter TRC. an agent to block the degrading enzyme for transmitter TRC, an antagonist for transmitter TRB, an agent to enhance the reuptake of transmitter TRB or a degrading enzyme for transmitter TRB. The agents can be infused separately or together in a cocktail. Such infusion leads to partial depolarization of neuron N2 and to a reduced threshold to stimulation by electrodes 38 and 40. That is, after infusion, the amplitude of stimulation required to create action potentials in neuron N2 is reduced compared to the time period before infusion, making it easier to electrically stimulate neuron N2 relative to neuron N3.
Referring to Figure 15, neurons N4-N6 have cells bodies CB4-CB6, respectively, and axons A4-A6, respectively, which are long fibers of passage that typically pass through white tissue in the spinal cord or brain. Cell bodies CB4-CB6 are located at portions of the body somewhat remote from infusion portions 27-29 and electrodes 38 and 40. However, a portions of axons A4-A6 pass in the region of infusion portions 27-29 and electrodes 38 and 40. Neurons N7-N9 have cell bodies that are located in the region of infusion portions 27-29 and electrodes 38 and 40. Neuron N7 can be inhibited at axon terminals AT7 by an inhibitory neurotransmitter TRA and excited at axon terminals AT8 by an excitatory neurotransmitter TRB; neuron N9 can be inhibited at axon terminals AT9 by inhibitory neurotransmitter
TRA and excited at axon terminals AT 10 by excitatory neurotransmitter TRB; and neuron N8 can be inhibited at axon terminals ATI 1 by inhibitory neurotransmitter TRA and excited at axon terminals AT 12 by an excitatory neurotransmitter TRB. Portions 27-29 are used to infuse an agonist of transmitter TRA. a reuptake blocker to transmitter TRA, a degrading enzyme blocker to transmitter TRA or an antagonist or degrading enzyme to transmitter TRB to raise the stimulation threshold of neurons N7-N9. Neurons N4-N6 are not affected by the infusion and can be selectively activated by stimulation supplied by electrodes 38 and 40.
Figure 16 illustrates a modified form of tube 22 A in which infusion portion 27 is located more than 0.01 cm from electrodes 38 and 40 and infusion portions 28-29 have been removed. Neuron N10 has a cell body CB10 and an axon Λ10 that terminates in axon terminals ATM. A neuron NI 1 can be excited at axon terminals ATM by an excitatory neurotransmitter TRA. Electrical stimulation of axon Al 0 causes the release of transmitter TRA at axon terminal ATM. Portion 27 is used to infuse an agent that blocks a degradative enzyme of transmitter TRA or an agent which blocks the reuptake of transmitter TRA. For each pulse administered by electrodes 38 and 40, the stimulation of neuron NI 1 is more potent. That is, more action potentials are generated in neuron Ni l .
Figure 18A illustrates various times at which infusion and stimulation can be applied by tube 22A. For example, infusion alone can be applied from time Tl to T2,
infusion and stimulation can be both be applied from time T2 to T3, and stimulation alone can be applied from time T3 to T4. This regimen might be used in the case when selective activation of one neuronal population is desired. By beginning the infusion before beginning stimulation during time Tl to T2, the threshold for electrical activation of one population of neurons can be lowered or raised as needed.
Another example would be if a precursor molecule, such as L-dopa, is infused to guard against depletion of transmitter substance. The stimulation might be applied periodically during the period of infusion either routinely or in response to sensor or patient generated demand as shown in figure 18B. Alternatively, the infusion of an agent to activate a neuronal population might be alternated with application of electrical stimulation of that same population, as shown in Figure 18C.
It also is possible to infuse an agent that has an affect upon the neuron population that is not strictly connected in time with the electrical depolarization of the neurons. In this case, the time of application of stimulation and infusion may be completely asynchronous. Or an agent could be infused that diffuses beyond the effects of the electrical stimulation but still has an advantageous effect on the brain independent of the stimulation effects. As an example, Figure 17 illustrates the same form of tube 22A shown in Figure 16 implanted adjacent a spinal cord SC. A steroid, or other anti-inflammatory drug, can be infused through portion 27 to reduce inflammation in area IN of the spinal cord, while portion ST, such as the dorsal columns, is electrically stimulated by electrodes 38 and 40 to treat the pain. Alternatively, an antispasmodic could be infused to treat the spasms associated with mechanical back problems while stimulation is applied to the spinal cord to treat the pain. By using the foregoing techniques for simultaneous drug infusion and electrical stimulation, neural disorders, including motor disorders, can be controlled with a degree of accuracy previously unattainable. Those skilled in that art will recognize that the preferred embodiments may be altered or amended without departing from the true spirit and scope of the invention, as defined in the accompanying claims.
Claims
1. A method of using one or more drugs to therapeutically treat a neural disorder over a predetermined time period by means of an implantable pump and a catheter having a proximal end coupled to said pump and a discharge portion for infusing therapeutic dosages of said one or more drugs, as well as a signal generator and an implantable electrode having a proximal end and a stimulation portion, said method comprising the steps of: surgically implanting said electrode so that the stimulation portion lies adjacent a predetermined stimulation site in subdural neural tissue; surgically implanting said catheter so that the discharge portion lies adjacent a predetermined infusion site in subdural neural tissue; coupling said proximal end of said electrode to said signal generator; operating said signal generator to stimulate said stimulation site during at least a portion of said predetermined time period; operating said pump to discharge a predetermined dosage of said one or more drugs through said discharge portion of said catheter into said infusion site during at least a portion of said predetermined time period, whereby said neural disorder is treated.
2. A method, as claimed in claim 1, wherein said neural disorder is a hyperkinetic disorder, wherein said stimulation site and said infusion site are in the brain, wherein said stimulation site and infusion site are selected from the group consisting of the ventrolateral thalamus (Thai), internal segment of globus pallidus (GPi), substantia nigra pars reticulata (SNr), subthalamic nucleus (STN), external segment of globus pallidus (GPe) and neostriatum, and wherein said stimulation and said discharge are selected to reduce thalamic output.
3. A method, as claimed in claim 2, wherein said hyperkinetic disorder comprises dystonia, ballism, hemiballism, chorea, athetosis, torticollis, or spasticity.
4. A method, as claimed in claim 2, wherein said stimulation and said discharge decreases excitement of the thalamus or increases inhibition of the thalamus.
5. A method, as claimed in claim 4, wherein said stimulation and discharge decreases inhibition or increases excitation of said internal segment of globus pallidus (GPi), substantia nigra pars reticulata (SNr) or subthalamic nucleus (STN) that inhibit thalamic output.
6. A method, as claimed in claim 4, wherein said stimulation and said discharge decreases excitation or increases inhibition of said external segment of globus pallidus (GPe).
7. A method, as claimed in claim 1 , wherein said stimulation comprises pulses having a repetition rate of 2 to 2500 Hz. or more.
8. A method, as claimed in claim 1 , wherein said movement disorder is a hypokinetic disorder, wherein said stimulation site and said infusion site are in the brain, wherein said stimulation site and infusion site are selected from the group consisting of the ventrolateral thalamus (Thai), internal segment of globus pallidus (GPi), substantia nigra pars reticulata (SNr), subthalamic nucleus (STN), external segment of globus pallidus (GPe) and neostriatum, and wherein said stimulation and said discharge are selected to increase thalamic output.
9. A method, as claimed in claim 8, wherein said hypokinetic disorder comprises Parkinson's disease, akinesia, rigidity, or bradykinesia.
10. A method, as claimed in claim 8, wherein said stimulation and said discharge increase excitement of the thalamus or decreases inhibition of the thalamus.
1 1. A method, as claimed in claim 10, wherein said stimulation and said discharge increase inhibition or decrease excitation of said internal segment of globus pallidus (GPi), substantia nigra pars reticulata (SNr) or subthalamic nucleus (STN) that inhibit thalamic output.
12. A method, as claimed in claim 10, wherein said stimulation and said discharge increase excitation or decrease inhibition of said external segment of globus pallidus (GPe).
13. A method, as claimed in claim 1, wherein said one or more drugs is selected from the group consisting of an antagonist of an inhibitory neurotransmitter acting on said neural tissue, an agonist of an excitatory neurotransmitter acting on said 39797 P S /05 2
27
neural tissue, a drug blocking the uptake of said excitatory neurotransmitter, a drug blocking the action ofa degradative enzyme of said excitatory neurotransmitter, a degradative enzyme for said inhibitory neurotransmitter and potassium, whereby the amplitude of said stimulation required to create an action potential in said neural tissue is reduced.
14. A method, as claimed in claim 1, wherein said neural tissue comprises a first neural tissue responsive to a first type of neurotransmitter and a second neural tissue responsive to a second type of neurotransmitter, and wherein said one or more drugs act on said first and second type of neurotransmitters so that said stimulation required to create an action potential in said first neural tissue is reduced compared to said stimulation required to create an action potential in said second neural tissue.
15. A method, as claimed in claim 14, wherein said neural tissue comprises a first neural tissue responsive to a first type of excitatory neurotransmitter and a second neural tissue responsive to a second type of excitatory neurotransmitter, wherein said one or more drugs is selected from the group consisting of an agonist of said first type of excitatory neurotransmitter acting on said neural tissue, a drug blocking the uptake of said first type of excitatory neurotransmitter, a degradative enzyme for said second type of excitatory neurotransmitter, whereby said stimulation required to create an action potential in said first neural tissue is reduced compared to said stimulation required to create an action potential in said second neural tissue.
16. A method as claimed in claim 14, wherein said neural tissue comprises a first neural tissue responsive to a first type of inhibitory neurotransmitter and a second neural tissue responsive to a second type of inhibitory neurotransmitter, wherein said one or more drugs is selected from the group consisting of an antagonist of said first type of inhibitory neurotransmitter acting on said neural tissue, a drug blocking the uptake of said second type of inhibitory neurotransmitter, a degradative enzyme for said first type of inhibitory neurotransmitter, whereby said stimulation required to create an action potential in said first neural tissue is reduced compared to said stimulation required to create an action potential in said second neural tissue.
17. A method, as claimed in claim 1 , wherein said neural tissue comprises a first neural tissue responsive to a first type of neurotransmitter and a second neural tissue comprising fibers of passage, and wherein said one or more drugs act on said first neural tissue so that said stimulation required to create an action potential in said first neural tissue is raised, whereby said fibers of passage can be stimulated without creating action potentials in said first neural tissue.
18. A method, as claimed in claim 1 , wherein said neural tissue comprises a first nerve comprising an axon that terminates in axon terminals and a second nerve comprising a cell body including a receiving cell that communicates with said axon terminals across a synapse by means of a neurotransmitter, wherein said stimulation site is adjacent said axon and wherein said infusion site is adjacent said synapse, and wherein one or more drugs is selected from the group consisting of a blocker of a degradative enzyme of said neurotransmitter and a drug blocking the reuptake of said neurotransmitter, whereby the said stimulation of said axon results in increased excitement of said second nerve.
19. A method, as claimed in claim 1 , wherein said neural tissue is a spinal cord, wherein said infusion site in located adjacent a first predetermined portion of said spinal cord and wherein said stimulation site is located adjacent a second predetermined portion of said spinal cord displaced from said first predetermined portion.
20. A system using one or more drugs to therapeutically treat a neural disorder comprising in combination: an implantable pump; a catheter having a proximal end coupled to said pump and a discharge portion adapted to infuse a therapeutic dosage of said one or more drugs into a predetermined infusion site in subdural neural tissue; an implantable signal generator; an implantable electrode having a proximal end coupled to said signal generator and a stimulation portion adapted to stimulate a predetermined stimulation site in said subdural neural tissue; a sensor for generating a sensor signal related to activity resulting from said neural disorder; and control means responsive to said sensor signal for regulating said stimulation and said therapeutic dosage, whereby said neural disorder is treated.
21. A system, as claimed in claim 20, wherein said sensor comprises a motion detector.
22. A system, as claimed in claim 20, wherein said sensor comprises means for detecting changes in electromagnetic waves generated by muscle or neural tissue.
23. A system, as claimed in claim 20, wherein said control means comprises a microprocessor.
24. A system, as claimed in claim 20, wherein said control means comprises an electrical filter.
25. A system, as claimed in claim 20, wherein said neural disorder is a hyperkinetic disorder or a hypokinetic disorder.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU24363/97A AU2436397A (en) | 1996-04-25 | 1997-04-02 | Method of treating movement disorders by brain stimulation and drug infusion |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/637,534 | 1996-04-25 | ||
US08/637,534 US6094598A (en) | 1996-04-25 | 1996-04-25 | Method of treating movement disorders by brain stimulation and drug infusion |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997039797A1 true WO1997039797A1 (en) | 1997-10-30 |
Family
ID=24556345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/005522 WO1997039797A1 (en) | 1996-04-25 | 1997-04-02 | Method of treating movement disorders by brain stimulation and drug infusion |
Country Status (3)
Country | Link |
---|---|
US (1) | US6094598A (en) |
AU (1) | AU2436397A (en) |
WO (1) | WO1997039797A1 (en) |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6094598A (en) * | 1996-04-25 | 2000-07-25 | Medtronics, Inc. | Method of treating movement disorders by brain stimulation and drug infusion |
EP1102607A2 (en) * | 1998-08-05 | 2001-05-30 | Daniel J. Dilorenzo | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
EP1048319A3 (en) * | 1999-04-30 | 2003-07-09 | Medtronic, Inc. | System for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve |
US7107104B2 (en) | 2003-05-30 | 2006-09-12 | Medtronic, Inc. | Implantable cortical neural lead and method |
US7160913B2 (en) | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
WO2008107822A1 (en) * | 2007-03-02 | 2008-09-12 | Koninklijke Philips Electronics N.V. | Electrode system for deep brain stimulation |
WO2009067610A1 (en) | 2007-11-20 | 2009-05-28 | The Cleveland Clinic Foundation | Systems and methods for neuromodulation using pre-recorded waveforms |
US7588581B2 (en) | 2002-03-26 | 2009-09-15 | Medtronic, Inc. | Placement of chronic micro-catheter device and method |
US7676263B2 (en) | 2006-06-23 | 2010-03-09 | Neurovista Corporation | Minimally invasive system for selecting patient-specific therapy parameters |
US7747325B2 (en) | 1998-08-05 | 2010-06-29 | Neurovista Corporation | Systems and methods for monitoring a patient's neurological disease state |
US7853329B2 (en) | 1998-08-05 | 2010-12-14 | Neurovista Corporation | Monitoring efficacy of neural modulation therapy |
US8036736B2 (en) | 2007-03-21 | 2011-10-11 | Neuro Vista Corporation | Implantable systems and methods for identifying a contra-ictal condition in a subject |
US8295934B2 (en) | 2006-11-14 | 2012-10-23 | Neurovista Corporation | Systems and methods of reducing artifact in neurological stimulation systems |
US8588933B2 (en) | 2009-01-09 | 2013-11-19 | Cyberonics, Inc. | Medical lead termination sleeve for implantable medical devices |
US8725243B2 (en) | 2005-12-28 | 2014-05-13 | Cyberonics, Inc. | Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
US8762065B2 (en) | 1998-08-05 | 2014-06-24 | Cyberonics, Inc. | Closed-loop feedback-driven neuromodulation |
US8786624B2 (en) | 2009-06-02 | 2014-07-22 | Cyberonics, Inc. | Processing for multi-channel signals |
US8849390B2 (en) | 2008-12-29 | 2014-09-30 | Cyberonics, Inc. | Processing for multi-channel signals |
US8868172B2 (en) | 2005-12-28 | 2014-10-21 | Cyberonics, Inc. | Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders |
US9042988B2 (en) | 1998-08-05 | 2015-05-26 | Cyberonics, Inc. | Closed-loop vagus nerve stimulation |
US9211408B2 (en) | 2005-04-13 | 2015-12-15 | The Cleveland Clinic Foundation | System and method for neuromodulation using composite patterns of stimulation or waveforms |
US9259591B2 (en) | 2007-12-28 | 2016-02-16 | Cyberonics, Inc. | Housing for an implantable medical device |
US9339650B2 (en) | 2005-04-13 | 2016-05-17 | The Cleveland Clinic Foundation | Systems and methods for neuromodulation using pre-recorded waveforms |
US9375573B2 (en) | 1998-08-05 | 2016-06-28 | Cyberonics, Inc. | Systems and methods for monitoring a patient's neurological disease state |
US9415222B2 (en) | 1998-08-05 | 2016-08-16 | Cyberonics, Inc. | Monitoring an epilepsy disease state with a supervisory module |
US9421373B2 (en) | 1998-08-05 | 2016-08-23 | Cyberonics, Inc. | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US9501829B2 (en) | 2011-03-29 | 2016-11-22 | Boston Scientific Neuromodulation Corporation | System and method for atlas registration |
US9526902B2 (en) | 2008-05-15 | 2016-12-27 | Boston Scientific Neuromodulation Corporation | VOA generation system and method using a fiber specific analysis |
US9545510B2 (en) | 2008-02-12 | 2017-01-17 | Intelect Medical, Inc. | Directional lead assembly with electrode anchoring prongs |
US9561380B2 (en) | 2012-08-28 | 2017-02-07 | Boston Scientific Neuromodulation Corporation | Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines |
US9592389B2 (en) | 2011-05-27 | 2017-03-14 | Boston Scientific Neuromodulation Corporation | Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information |
US9604067B2 (en) | 2012-08-04 | 2017-03-28 | Boston Scientific Neuromodulation Corporation | Techniques and methods for storing and transferring registration, atlas, and lead information between medical devices |
US9622675B2 (en) | 2007-01-25 | 2017-04-18 | Cyberonics, Inc. | Communication error alerting in an epilepsy monitoring system |
US9643019B2 (en) | 2010-02-12 | 2017-05-09 | Cyberonics, Inc. | Neurological monitoring and alerts |
US9760688B2 (en) | 2004-07-07 | 2017-09-12 | Cleveland Clinic Foundation | Method and device for displaying predicted volume of influence |
US9776003B2 (en) | 2009-12-02 | 2017-10-03 | The Cleveland Clinic Foundation | Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming |
US9788744B2 (en) | 2007-07-27 | 2017-10-17 | Cyberonics, Inc. | Systems for monitoring brain activity and patient advisory device |
US9792412B2 (en) | 2012-11-01 | 2017-10-17 | Boston Scientific Neuromodulation Corporation | Systems and methods for VOA model generation and use |
US9867989B2 (en) | 2010-06-14 | 2018-01-16 | Boston Scientific Neuromodulation Corporation | Programming interface for spinal cord neuromodulation |
US9898656B2 (en) | 2007-01-25 | 2018-02-20 | Cyberonics, Inc. | Systems and methods for identifying a contra-ictal condition in a subject |
US9925382B2 (en) | 2011-08-09 | 2018-03-27 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related volume analysis, creation, and sharing |
US9956419B2 (en) | 2015-05-26 | 2018-05-01 | Boston Scientific Neuromodulation Corporation | Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation |
US9959388B2 (en) | 2014-07-24 | 2018-05-01 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for providing electrical stimulation therapy feedback |
US9974959B2 (en) | 2014-10-07 | 2018-05-22 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters |
US10071249B2 (en) | 2015-10-09 | 2018-09-11 | Boston Scientific Neuromodulation Corporation | System and methods for clinical effects mapping for directional stimulation leads |
US10265528B2 (en) | 2014-07-30 | 2019-04-23 | Boston Scientific Neuromodulation Corporation | Systems and methods for electrical stimulation-related patient population volume analysis and use |
US10272247B2 (en) | 2014-07-30 | 2019-04-30 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming |
US10350404B2 (en) | 2016-09-02 | 2019-07-16 | Boston Scientific Neuromodulation Corporation | Systems and methods for visualizing and directing stimulation of neural elements |
US10360511B2 (en) | 2005-11-28 | 2019-07-23 | The Cleveland Clinic Foundation | System and method to estimate region of tissue activation |
US10434302B2 (en) | 2008-02-11 | 2019-10-08 | Intelect Medical, Inc. | Directional electrode devices with locating features |
US10441800B2 (en) | 2015-06-29 | 2019-10-15 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting stimulation parameters by targeting and steering |
US10589104B2 (en) | 2017-01-10 | 2020-03-17 | Boston Scientific Neuromodulation Corporation | Systems and methods for creating stimulation programs based on user-defined areas or volumes |
US10603498B2 (en) | 2016-10-14 | 2020-03-31 | Boston Scientific Neuromodulation Corporation | Systems and methods for closed-loop determination of stimulation parameter settings for an electrical simulation system |
US10625082B2 (en) | 2017-03-15 | 2020-04-21 | Boston Scientific Neuromodulation Corporation | Visualization of deep brain stimulation efficacy |
US10716505B2 (en) | 2017-07-14 | 2020-07-21 | Boston Scientific Neuromodulation Corporation | Systems and methods for estimating clinical effects of electrical stimulation |
US10716942B2 (en) | 2016-04-25 | 2020-07-21 | Boston Scientific Neuromodulation Corporation | System and methods for directional steering of electrical stimulation |
US10776456B2 (en) | 2016-06-24 | 2020-09-15 | Boston Scientific Neuromodulation Corporation | Systems and methods for visual analytics of clinical effects |
US10780282B2 (en) | 2016-09-20 | 2020-09-22 | Boston Scientific Neuromodulation Corporation | Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters |
US10780283B2 (en) | 2015-05-26 | 2020-09-22 | Boston Scientific Neuromodulation Corporation | Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation |
US10792501B2 (en) | 2017-01-03 | 2020-10-06 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting MRI-compatible stimulation parameters |
US10960214B2 (en) | 2017-08-15 | 2021-03-30 | Boston Scientific Neuromodulation Corporation | Systems and methods for controlling electrical stimulation using multiple stimulation fields |
US11160981B2 (en) | 2015-06-29 | 2021-11-02 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects |
US11285329B2 (en) | 2018-04-27 | 2022-03-29 | Boston Scientific Neuromodulation Corporation | Systems and methods for visualizing and programming electrical stimulation |
US11298553B2 (en) | 2018-04-27 | 2022-04-12 | Boston Scientific Neuromodulation Corporation | Multi-mode electrical stimulation systems and methods of making and using |
US11357986B2 (en) | 2017-04-03 | 2022-06-14 | Boston Scientific Neuromodulation Corporation | Systems and methods for estimating a volume of activation using a compressed database of threshold values |
US11406317B2 (en) | 2007-12-28 | 2022-08-09 | Livanova Usa, Inc. | Method for detecting neurological and clinical manifestations of a seizure |
Families Citing this family (194)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060089751A1 (en) * | 1997-01-27 | 2006-04-27 | Ewa Herbst | Electronic delivery systems and methods with feedback |
US7799337B2 (en) * | 1997-07-21 | 2010-09-21 | Levin Bruce H | Method for directed intranasal administration of a composition |
US6227203B1 (en) | 1998-02-12 | 2001-05-08 | Medtronic, Inc. | Techniques for controlling abnormal involuntary movements by brain stimulation and drug infusion |
US7231254B2 (en) * | 1998-08-05 | 2007-06-12 | Bioneuronics Corporation | Closed-loop feedback-driven neuromodulation |
US7974696B1 (en) | 1998-08-05 | 2011-07-05 | Dilorenzo Biomedical, Llc | Closed-loop autonomic neuromodulation for optimal control of neurological and metabolic disease |
US7242984B2 (en) * | 1998-08-05 | 2007-07-10 | Neurovista Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US6343226B1 (en) * | 1999-06-25 | 2002-01-29 | Neurokinetic Aps | Multifunction electrode for neural tissue stimulation |
US6704603B1 (en) * | 2000-05-16 | 2004-03-09 | Lockheed Martin Corporation | Adaptive stimulator for relief of symptoms of neurological disorders |
US6306403B1 (en) * | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
US6526318B1 (en) * | 2000-06-16 | 2003-02-25 | Mehdi M. Ansarinia | Stimulation method for the sphenopalatine ganglia, sphenopalatine nerve, or vidian nerve for treatment of medical conditions |
US7756584B2 (en) | 2000-07-13 | 2010-07-13 | Advanced Neuromodulation Systems, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7831305B2 (en) | 2001-10-15 | 2010-11-09 | Advanced Neuromodulation Systems, Inc. | Neural stimulation system and method responsive to collateral neural activity |
US7305268B2 (en) | 2000-07-13 | 2007-12-04 | Northstar Neurscience, Inc. | Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators |
US6497699B1 (en) * | 2000-08-09 | 2002-12-24 | The Research Foundation Of State University Of New York | Hybrid neuroprosthesis for the treatment of brain disorders |
US6405079B1 (en) * | 2000-09-22 | 2002-06-11 | Mehdi M. Ansarinia | Stimulation method for the dural venous sinuses and adjacent dura for treatment of medical conditions |
US6529774B1 (en) | 2000-11-09 | 2003-03-04 | Neuropace, Inc. | Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation |
US6950707B2 (en) * | 2000-11-21 | 2005-09-27 | Advanced Bionics Corporation | Systems and methods for treatment of obesity and eating disorders by electrical brain stimulation and/or drug infusion |
US7440806B1 (en) | 2000-11-21 | 2008-10-21 | Boston Scientific Neuromodulation Corp. | Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion |
US7493171B1 (en) | 2000-11-21 | 2009-02-17 | Boston Scientific Neuromodulation Corp. | Treatment of pathologic craving and aversion syndromes and eating disorders by electrical brain stimulation and/or drug infusion |
US6922590B1 (en) * | 2000-11-21 | 2005-07-26 | Advanced Bionics Corporation | Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion |
US20030073608A1 (en) * | 2001-04-10 | 2003-04-17 | Woolf Nancy J. | Process for treating disease |
US6907295B2 (en) | 2001-08-31 | 2005-06-14 | Biocontrol Medical Ltd. | Electrode assembly for nerve control |
US6892098B2 (en) | 2001-04-26 | 2005-05-10 | Biocontrol Medical Ltd. | Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders |
US6606521B2 (en) | 2001-07-09 | 2003-08-12 | Neuropace, Inc. | Implantable medical lead |
US20060241717A1 (en) * | 2001-08-30 | 2006-10-26 | Whitehurst Todd K | Treatment of movement disorders by extra dural motor cortex stimulation |
US7778703B2 (en) * | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Selective nerve fiber stimulation for treating heart conditions |
US8571653B2 (en) | 2001-08-31 | 2013-10-29 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
US7778711B2 (en) * | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Reduction of heart rate variability by parasympathetic stimulation |
US7904176B2 (en) | 2006-09-07 | 2011-03-08 | Bio Control Medical (B.C.M.) Ltd. | Techniques for reducing pain associated with nerve stimulation |
US7885709B2 (en) * | 2001-08-31 | 2011-02-08 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation for treating disorders |
US7974693B2 (en) | 2001-08-31 | 2011-07-05 | Bio Control Medical (B.C.M.) Ltd. | Techniques for applying, configuring, and coordinating nerve fiber stimulation |
US7734355B2 (en) | 2001-08-31 | 2010-06-08 | Bio Control Medical (B.C.M.) Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US6899692B2 (en) * | 2001-10-17 | 2005-05-31 | Transvivo, Inc. | Plasmapheresis filter device and catheter assembly |
US6944497B2 (en) * | 2001-10-31 | 2005-09-13 | Medtronic, Inc. | System and method of treating stuttering by neuromodulation |
US6788976B2 (en) | 2001-11-02 | 2004-09-07 | Lockheed Martin Corporation | Movement timing simulator |
US20030105409A1 (en) | 2001-11-14 | 2003-06-05 | Donoghue John Philip | Neurological signal decoding |
GB0204288D0 (en) * | 2002-02-23 | 2002-04-10 | Univ Reading | A biomedical device |
DE10211765B4 (en) * | 2002-03-14 | 2004-06-03 | Forschungszentrum Jülich GmbH | Device for localizing the target point of electrodes for brain stimulation, in particular for deep brain stimulation |
US7283861B2 (en) * | 2002-04-30 | 2007-10-16 | Alexander Bystritsky | Methods for modifying electrical currents in neuronal circuits |
US8086296B2 (en) * | 2002-04-30 | 2011-12-27 | Brainsonix Corporation | Methods for modifying electrical currents in neuronal circuits |
US9592409B2 (en) | 2002-04-30 | 2017-03-14 | The Regents Of The University Of California | Methods for modifying electrical currents in neuronal circuits |
WO2004110550A2 (en) * | 2003-06-13 | 2004-12-23 | Biocontrol Medical Ltd. | Vagal stimulation for anti-embolic therapy |
US8204591B2 (en) * | 2002-05-23 | 2012-06-19 | Bio Control Medical (B.C.M.) Ltd. | Techniques for prevention of atrial fibrillation |
US7561922B2 (en) * | 2004-12-22 | 2009-07-14 | Biocontrol Medical Ltd. | Construction of electrode assembly for nerve control |
US7321793B2 (en) | 2003-06-13 | 2008-01-22 | Biocontrol Medical Ltd. | Vagal stimulation for atrial fibrillation therapy |
US20050065553A1 (en) * | 2003-06-13 | 2005-03-24 | Omry Ben Ezra | Applications of vagal stimulation |
US7844346B2 (en) * | 2002-05-23 | 2010-11-30 | Biocontrol Medical Ltd. | Electrode assembly for nerve control |
US7151961B1 (en) * | 2002-05-24 | 2006-12-19 | Advanced Bionics Corporation | Treatment of movement disorders by brain stimulation |
US7285118B1 (en) | 2002-07-18 | 2007-10-23 | Functional Neuroscience Inc. | Brain stimulation lead used for lesioning |
WO2004036370A2 (en) * | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Channel-selective blanking for a medical device system |
AU2003285889A1 (en) * | 2002-10-15 | 2004-05-04 | Medtronic Inc. | Control of treatment therapy during start-up and during operation of a medical device system |
US7933646B2 (en) * | 2002-10-15 | 2011-04-26 | Medtronic, Inc. | Clustering of recorded patient neurological activity to determine length of a neurological event |
WO2004036372A2 (en) * | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Scoring of sensed neurological signals for use with a medical device system |
EP1629341A4 (en) * | 2002-10-15 | 2008-10-15 | Medtronic Inc | Multi-modal operation of a medical device system |
ATE449561T1 (en) * | 2002-10-15 | 2009-12-15 | Medtronic Inc | PHASE SHIFT OF NEUROLOGICAL SIGNALS IN A MEDICAL DEVICE SYSTEM |
US8543214B2 (en) * | 2002-10-15 | 2013-09-24 | Medtronic, Inc. | Configuring and testing treatment therapy parameters for a medical device system |
AU2003287159A1 (en) * | 2002-10-15 | 2004-05-04 | Medtronic Inc. | Synchronization and calibration of clocks for a medical device and calibrated clock |
WO2004034997A2 (en) * | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Medical device system with relaying module for treatment of nervous system disorders |
EP1583464B1 (en) * | 2002-10-15 | 2014-04-09 | Medtronic, Inc. | Clustering of recorded patient neurological activity to determine length of a neurological event |
US20040138647A1 (en) * | 2002-10-15 | 2004-07-15 | Medtronic, Inc. | Cycle mode providing redundant back-up to ensure termination of treatment therapy in a medical device system |
AU2003286451A1 (en) * | 2002-10-15 | 2004-05-04 | Medtronic Inc. | Signal quality monitoring and control for a medical device system |
EP1558130A4 (en) * | 2002-10-15 | 2009-01-28 | Medtronic Inc | Screening techniques for management of a nervous system disorder |
AU2003278006A1 (en) * | 2002-10-15 | 2004-05-04 | Creo Inc. | Automated information management system and methods |
US7212851B2 (en) * | 2002-10-24 | 2007-05-01 | Brown University Research Foundation | Microstructured arrays for cortex interaction and related methods of manufacture and use |
DE60314000D1 (en) * | 2002-10-24 | 2007-07-05 | Lockheed Corp | SYSTEM FOR TREATING MOTION MALFUNCTIONS |
WO2004043536A1 (en) * | 2002-11-12 | 2004-05-27 | Neuropace, Inc. | System for adaptive brain stimulation |
US8880192B2 (en) | 2012-04-02 | 2014-11-04 | Bio Control Medical (B.C.M.) Ltd. | Electrode cuffs |
US7627384B2 (en) | 2004-11-15 | 2009-12-01 | Bio Control Medical (B.C.M.) Ltd. | Techniques for nerve stimulation |
US7155279B2 (en) * | 2003-03-28 | 2006-12-26 | Advanced Bionics Corporation | Treatment of movement disorders with drug therapy |
US7963956B2 (en) * | 2003-04-22 | 2011-06-21 | Antisense Pharma Gmbh | Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique |
US20040225335A1 (en) * | 2003-05-08 | 2004-11-11 | Whitehurst Todd K. | Treatment of Huntington's disease by brain stimulation |
US8060197B2 (en) * | 2003-05-23 | 2011-11-15 | Bio Control Medical (B.C.M.) Ltd. | Parasympathetic stimulation for termination of non-sinus atrial tachycardia |
CA2432810A1 (en) * | 2003-06-19 | 2004-12-19 | Andres M. Lozano | Method of treating depression, mood disorders and anxiety disorders by brian infusion |
WO2005011805A2 (en) | 2003-08-01 | 2005-02-10 | Northstar Neuroscience, Inc. | Apparatus and methods for applying neural stimulation to a patient |
US20080208288A1 (en) * | 2003-10-24 | 2008-08-28 | Lockheed Martin Corporation | Systems and methods for treating movement disorders |
US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8617572B2 (en) * | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8609113B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8609112B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US20050113744A1 (en) * | 2003-11-21 | 2005-05-26 | Cyberkinetics, Inc. | Agent delivery systems and related methods under control of biological electrical signals |
US20050234309A1 (en) * | 2004-01-07 | 2005-10-20 | David Klapper | Method and apparatus for classification of movement states in Parkinson's disease |
US7717848B2 (en) | 2004-03-16 | 2010-05-18 | Medtronic, Inc. | Collecting sleep quality information via a medical device |
US8725244B2 (en) | 2004-03-16 | 2014-05-13 | Medtronic, Inc. | Determination of sleep quality for neurological disorders |
US20050214217A1 (en) * | 2004-03-26 | 2005-09-29 | Mai Levite | Methods of and pharmaceutical compositions for modulating T-lymphocyte adhesion, migration, gene expression and function by Glutamate and analogs thereof |
GB0409109D0 (en) * | 2004-04-23 | 2004-05-26 | Medtronic Inc | Deep brain stimulation |
US7313442B2 (en) * | 2004-04-30 | 2007-12-25 | Advanced Neuromodulation Systems, Inc. | Method of treating mood disorders and/or anxiety disorders by brain stimulation |
DE102004025825A1 (en) * | 2004-05-24 | 2005-12-29 | Forschungszentrum Jülich GmbH | Apparatus for treating patients by brain stimulation, an electronic component and the use of the device and the electronic component in medicine and medical treatment method |
JP5175092B2 (en) | 2004-06-01 | 2013-04-03 | クワラタ トレーディング リミティド | In vitro technology using stem cells |
JP2008506464A (en) | 2004-07-15 | 2008-03-06 | ノーススター ニューロサイエンス インコーポレイテッド | System and method for enhancing or influencing neural stimulation efficiency and / or efficacy |
EP1786509A4 (en) * | 2004-07-27 | 2010-01-13 | Cleveland Clinic Foundation | Thalamic stimulation device |
US20060058627A1 (en) * | 2004-08-13 | 2006-03-16 | Flaherty J C | Biological interface systems with wireless connection and related methods |
US8560041B2 (en) * | 2004-10-04 | 2013-10-15 | Braingate Co., Llc | Biological interface system |
US20060110374A1 (en) * | 2004-11-24 | 2006-05-25 | Dudy Czeiger | Method to accelerate stem cell recruitment and homing |
US7483746B2 (en) * | 2004-12-06 | 2009-01-27 | Boston Scientific Neuromodulation Corp. | Stimulation of the stomach in response to sensed parameters to treat obesity |
DE102004060514A1 (en) * | 2004-12-16 | 2006-06-29 | Forschungszentrum Jülich GmbH | Method and apparatus for desynchronizing neuronal brain activity, control, and methods for treating neuronal and / or psychiatric disorders |
US8612006B2 (en) * | 2004-12-17 | 2013-12-17 | Functional Neuromodulation | Inducing neurogenesis within a human brain |
US10384053B2 (en) | 2004-12-17 | 2019-08-20 | Functional Neuromodulation Inc. | Inducing neurogenesis within a human brain |
US20060161217A1 (en) * | 2004-12-21 | 2006-07-20 | Jaax Kristen N | Methods and systems for treating obesity |
US8515541B1 (en) * | 2004-12-22 | 2013-08-20 | Boston Scientific Neuromodulation Corporation | Methods and systems for treating post-stroke disorders |
WO2006074029A2 (en) * | 2005-01-06 | 2006-07-13 | Cyberkinetics Neurotechnology Systems, Inc. | Neurally controlled and multi-device patient ambulation systems and related methods |
US20060253166A1 (en) * | 2005-01-06 | 2006-11-09 | Flaherty J C | Patient training routine for biological interface system |
US8095209B2 (en) * | 2005-01-06 | 2012-01-10 | Braingate Co., Llc | Biological interface system with gated control signal |
US20060167564A1 (en) * | 2005-01-10 | 2006-07-27 | Flaherty J C | Limb and digit movement system |
US8812096B2 (en) * | 2005-01-10 | 2014-08-19 | Braingate Co., Llc | Biological interface system with patient training apparatus |
WO2006078432A2 (en) * | 2005-01-18 | 2006-07-27 | Cyberkinetics Neurotechnology Systems, Inc. | Biological interface system with automated configuration |
US8609082B2 (en) | 2005-01-25 | 2013-12-17 | Bio Control Medical Ltd. | Administering bone marrow progenitor cells or myoblasts followed by application of an electrical current for cardiac repair, increasing blood supply or enhancing angiogenesis |
AU2006218642A1 (en) * | 2005-03-01 | 2006-09-08 | Advanced Neuromodulation Systems, Inc. | Method of treating depression, mood disorders and anxiety disorders using neuromodulation |
US20060212090A1 (en) * | 2005-03-01 | 2006-09-21 | Functional Neuroscience Inc. | Method of treating cognitive disorders using neuromodulation |
US8702629B2 (en) | 2005-03-17 | 2014-04-22 | Great Lakes Neuro Technologies Inc. | Movement disorder recovery system and method for continuous monitoring |
US8831739B2 (en) * | 2005-06-02 | 2014-09-09 | Huntington Medical Research Institutes | Microelectrode array for chronic deep-brain microstimulation for recording |
US7890166B2 (en) * | 2005-06-09 | 2011-02-15 | Medtronic, Inc. | Regional therapies for treatment of pain |
EP1743665B1 (en) * | 2005-07-15 | 2015-03-11 | Imec | Neurotransmitter stimulation of neurons with feedback from sensors |
US7729773B2 (en) * | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
US20070106143A1 (en) * | 2005-11-08 | 2007-05-10 | Flaherty J C | Electrode arrays and related methods |
US20100023021A1 (en) * | 2005-12-27 | 2010-01-28 | Flaherty J Christopher | Biological Interface and Insertion |
US20070156126A1 (en) * | 2005-12-29 | 2007-07-05 | Flaherty J C | Medical device insertion system and related methods |
US20070149952A1 (en) | 2005-12-28 | 2007-06-28 | Mike Bland | Systems and methods for characterizing a patient's propensity for a neurological event and for communicating with a pharmacological agent dispenser |
US20070179558A1 (en) * | 2006-01-30 | 2007-08-02 | Gliner Bradford E | Systems and methods for varying electromagnetic and adjunctive neural therapies |
TW200734462A (en) | 2006-03-08 | 2007-09-16 | In Motion Invest Ltd | Regulating stem cells |
US20070213796A1 (en) * | 2006-03-10 | 2007-09-13 | Mcginnis William J | Ring electrode |
WO2007112092A2 (en) | 2006-03-24 | 2007-10-04 | Medtronic, Inc. | Collecting gait information for evaluation and control of therapy |
US8326431B2 (en) * | 2006-04-28 | 2012-12-04 | Medtronic, Inc. | Implantable medical device for the concurrent treatment of a plurality of neurological disorders and method therefore |
US8892200B2 (en) | 2006-06-19 | 2014-11-18 | Highland Instruments, Inc. | Systems and methods for stimulating tissue using focused energy |
JP5250549B2 (en) | 2006-06-19 | 2013-07-31 | ハイランド インストゥルメンツ, インコーポレイテッド | Apparatus and method for stimulation of biological tissue |
US8718758B2 (en) * | 2006-06-19 | 2014-05-06 | Highland Instruments, Inc. | Interface apparatus for stimulation of biological tissue |
US9913976B2 (en) | 2006-06-19 | 2018-03-13 | Highland Instruments, Inc. | Systems and methods for stimulating and monitoring biological tissue |
US8321025B2 (en) | 2006-07-31 | 2012-11-27 | Cranial Medical Systems, Inc. | Lead and methods for brain monitoring and modulation |
US7583999B2 (en) * | 2006-07-31 | 2009-09-01 | Cranial Medical Systems, Inc. | Multi-channel connector for brain stimulation system |
US8538536B2 (en) * | 2007-04-20 | 2013-09-17 | The Cleveland Clinic Foundation | Methods of improving neuropsychological function in patients with neurocognitive disorders |
WO2009026382A1 (en) * | 2007-08-20 | 2009-02-26 | Kopell, Brian, H. | Systems and methods for treating neurological disorders by light stimulation |
US8380314B2 (en) | 2007-09-26 | 2013-02-19 | Medtronic, Inc. | Patient directed therapy control |
US20090264789A1 (en) * | 2007-09-26 | 2009-10-22 | Medtronic, Inc. | Therapy program selection |
US8147480B2 (en) | 2007-09-28 | 2012-04-03 | Codman & Shurtleff, Inc. | Catheter for reduced reflux in targeted tissue delivery of a therapeutic agent |
US7766875B2 (en) * | 2007-09-28 | 2010-08-03 | Codman & Shurtleff, Inc. | Catheter for reduced reflux in targeted tissue delivery of a therapeutic agent |
US8121694B2 (en) * | 2007-10-16 | 2012-02-21 | Medtronic, Inc. | Therapy control based on a patient movement state |
ES2562618T3 (en) | 2007-10-26 | 2016-03-07 | Boston Scientific Neuromodulation Corporation | Drill hole plug designs |
WO2009073891A1 (en) * | 2007-12-07 | 2009-06-11 | Northstar Neuroscience, Inc. | Systems and methods for providing targeted neural stimulation therapy to address neurological disorders, including neuropyschiatric and neuropyschological disorders |
CN101925377A (en) | 2008-01-25 | 2010-12-22 | 麦德托尼克公司 | The detection of Sleep stages |
US8473062B2 (en) | 2008-05-01 | 2013-06-25 | Autonomic Technologies, Inc. | Method and device for the treatment of headache |
WO2009140283A1 (en) * | 2008-05-13 | 2009-11-19 | The Board Of Trustees Of The University Of Illinois | Apparatus for managing a neurological disorder |
EP3536376A1 (en) | 2008-07-30 | 2019-09-11 | Ecole Polytechnique Fédérale de Lausanne | Apparatus for optimized stimulation of a neurological target |
US8335551B2 (en) * | 2008-09-29 | 2012-12-18 | Chong Il Lee | Method and means for connecting a large number of electrodes to a measuring device |
US8280516B2 (en) * | 2008-10-09 | 2012-10-02 | Daniel Graupe | Method and apparatus for closed-loop deep brain stimulation in treating neurological diseases |
JP5667987B2 (en) * | 2008-11-12 | 2015-02-12 | エコーレ ポリテクニーク フェデラーレ デ ローザンヌ (イーピーエフエル) | Micromachined nerve stimulation device |
US8412336B2 (en) | 2008-12-29 | 2013-04-02 | Autonomic Technologies, Inc. | Integrated delivery and visualization tool for a neuromodulation system |
US9320908B2 (en) | 2009-01-15 | 2016-04-26 | Autonomic Technologies, Inc. | Approval per use implanted neurostimulator |
US8494641B2 (en) | 2009-04-22 | 2013-07-23 | Autonomic Technologies, Inc. | Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism |
EP2411090B1 (en) * | 2009-03-22 | 2015-08-19 | Sorin CRM SAS | Optimal deep brain stimulation therapy with q learning |
US9770204B2 (en) * | 2009-11-11 | 2017-09-26 | Medtronic, Inc. | Deep brain stimulation for sleep and movement disorders |
JP2013512062A (en) | 2009-12-01 | 2013-04-11 | エコーレ ポリテクニーク フェデラーレ デ ローザンヌ | Microfabricated surface nerve stimulation device and methods of making and using the same |
US9549708B2 (en) | 2010-04-01 | 2017-01-24 | Ecole Polytechnique Federale De Lausanne | Device for interacting with neurological tissue and methods of making and using the same |
US8788045B2 (en) | 2010-06-08 | 2014-07-22 | Bluewind Medical Ltd. | Tibial nerve stimulation |
US9211411B2 (en) | 2010-08-26 | 2015-12-15 | Medtronic, Inc. | Therapy for rapid eye movement behavior disorder (RBD) |
US8583237B2 (en) | 2010-09-13 | 2013-11-12 | Cranial Medical Systems, Inc. | Devices and methods for tissue modulation and monitoring |
WO2012054560A1 (en) | 2010-10-21 | 2012-04-26 | Highland Instruments, Inc. | Methods for detecting a condition |
US9457186B2 (en) | 2010-11-15 | 2016-10-04 | Bluewind Medical Ltd. | Bilateral feedback |
US9186504B2 (en) | 2010-11-15 | 2015-11-17 | Rainbow Medical Ltd | Sleep apnea treatment |
US9352153B2 (en) | 2011-01-24 | 2016-05-31 | Cochlear Limited | Systems and methods for detecting nerve stimulation with an implanted prosthesis |
US8594783B2 (en) | 2011-08-24 | 2013-11-26 | Highland Instruments, Inc. | Systems and methods for stimulating cellular function in tissue |
US20150018728A1 (en) | 2012-01-26 | 2015-01-15 | Bluewind Medical Ltd. | Wireless neurostimulators |
WO2014087337A1 (en) | 2012-12-06 | 2014-06-12 | Bluewind Medical Ltd. | Delivery of implantable neurostimulators |
US10512794B2 (en) | 2016-12-16 | 2019-12-24 | Brainsonix Corporation | Stereotactic frame |
US10974078B2 (en) | 2012-12-27 | 2021-04-13 | Brainsonix Corporation | Treating degenerative dementia with low intensity focused ultrasound pulsation (LIFUP) device |
US9061133B2 (en) | 2012-12-27 | 2015-06-23 | Brainsonix Corporation | Focused ultrasonic transducer navigation system |
US9119964B2 (en) * | 2013-03-06 | 2015-09-01 | Boston Scientific Neuromodulation Corporation | System for deep brain stimulation employing a sensor for monitoring patient movement and providing closed loop control |
US9370660B2 (en) | 2013-03-29 | 2016-06-21 | Rainbow Medical Ltd. | Independently-controlled bidirectional nerve stimulation |
US9950173B2 (en) * | 2013-06-06 | 2018-04-24 | Boston Scientific Neuromodulation Corporation | System and method for delivering sub-threshold and super-threshold therapy to a patient |
US11311718B2 (en) | 2014-05-16 | 2022-04-26 | Aleva Neurotherapeutics Sa | Device for interacting with neurological tissue and methods of making and using the same |
EP3476430B1 (en) | 2014-05-16 | 2020-07-01 | Aleva Neurotherapeutics SA | Device for interacting with neurological tissue |
US9474894B2 (en) | 2014-08-27 | 2016-10-25 | Aleva Neurotherapeutics | Deep brain stimulation lead |
US9403011B2 (en) | 2014-08-27 | 2016-08-02 | Aleva Neurotherapeutics | Leadless neurostimulator |
USD759803S1 (en) | 2014-10-28 | 2016-06-21 | Highland Instruments, Inc. | Adjustable headpiece with anatomical markers |
US9597521B2 (en) | 2015-01-21 | 2017-03-21 | Bluewind Medical Ltd. | Transmitting coils for neurostimulation |
US9764146B2 (en) | 2015-01-21 | 2017-09-19 | Bluewind Medical Ltd. | Extracorporeal implant controllers |
US10004896B2 (en) | 2015-01-21 | 2018-06-26 | Bluewind Medical Ltd. | Anchors and implant devices |
US9782589B2 (en) | 2015-06-10 | 2017-10-10 | Bluewind Medical Ltd. | Implantable electrostimulator for improving blood flow |
US10232169B2 (en) | 2015-07-23 | 2019-03-19 | Boston Scientific Neuromodulation Corporation | Burr hole plugs for electrical stimulation systems and methods of making and using |
US10105540B2 (en) | 2015-11-09 | 2018-10-23 | Bluewind Medical Ltd. | Optimization of application of current |
US9713707B2 (en) | 2015-11-12 | 2017-07-25 | Bluewind Medical Ltd. | Inhibition of implant migration |
CN109069824B (en) | 2016-02-02 | 2022-09-16 | 阿莱瓦神经治疗股份有限公司 | Treatment of autoimmune diseases using deep brain stimulation |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
WO2018039117A1 (en) | 2016-08-22 | 2018-03-01 | Boston Scientific Neuromodulation Corporation | Neuromodulation system for providing paresthesia and analgesia and a system with leads and with electrodes |
US10124178B2 (en) | 2016-11-23 | 2018-11-13 | Bluewind Medical Ltd. | Implant and delivery tool therefor |
US20180353764A1 (en) | 2017-06-13 | 2018-12-13 | Bluewind Medical Ltd. | Antenna configuration |
US11596795B2 (en) | 2017-07-31 | 2023-03-07 | Medtronic, Inc. | Therapeutic electrical stimulation therapy for patient gait freeze |
US11103716B2 (en) | 2017-11-13 | 2021-08-31 | Boston Scientific Neuromodulation Corporation | Systems and methods for making and using a low-profile control module for an electrical stimulation system |
US11497914B2 (en) | 2018-01-16 | 2022-11-15 | Boston Scientific Neuromodulation Corporation | Systems and methods for making and using an electrical stimulation system with a case-neutral battery |
US10702692B2 (en) | 2018-03-02 | 2020-07-07 | Aleva Neurotherapeutics | Neurostimulation device |
US11058870B2 (en) | 2018-03-09 | 2021-07-13 | Boston Scientific Neuromodulation Corporation | Burr hole plugs for electrical stimulation systems and methods of making and using |
US11013913B2 (en) | 2018-03-16 | 2021-05-25 | Boston Scientific Neuromodulation Corporation | Kits and methods for securing a burr hole plugs for stimulation systems |
US20210361865A1 (en) * | 2019-10-04 | 2021-11-25 | Arnold Chase | Intelligent drug delivery system |
US20210260284A1 (en) * | 2019-10-04 | 2021-08-26 | Arnold Chase | Intelligent drug delivery system |
US11759661B2 (en) | 2020-05-20 | 2023-09-19 | Brainsonix Corporation | Ultrasonic transducer treatment device |
US11400299B1 (en) | 2021-09-14 | 2022-08-02 | Rainbow Medical Ltd. | Flexible antenna for stimulator |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4146029A (en) * | 1974-04-23 | 1979-03-27 | Ellinwood Jr Everett H | Self-powered implanted programmable medication system and method |
WO1985001213A1 (en) * | 1983-09-14 | 1985-03-28 | Jacob Zabara | Neurocybernetic prosthesis |
WO1991001756A1 (en) * | 1989-08-11 | 1991-02-21 | Skolnick Malcolm H | Method for chemical promotion of the effects of low current transcranial electrostimulation |
US5058584A (en) * | 1990-08-30 | 1991-10-22 | Medtronic, Inc. | Method and apparatus for epidural burst stimulation for angina pectoris |
US5081990A (en) * | 1990-05-11 | 1992-01-21 | New York University | Catheter for spinal epidural injection of drugs and measurement of evoked potentials |
WO1992007605A1 (en) * | 1990-11-05 | 1992-05-14 | Ravi Xavier | Implantable drug dispensing multielectrode catheter |
US5423877A (en) * | 1992-05-04 | 1995-06-13 | David C. Mackey | Method and device for acute pain management by simultaneous spinal cord electrical stimulation and drug infusion |
DE19509609A1 (en) * | 1994-04-25 | 1995-10-26 | Siemens Elema Ab | Medical device |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4692147A (en) * | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
US5871472A (en) * | 1987-11-17 | 1999-02-16 | Brown University Research Foundation | Planting devices for the focal release of neuroinhibitory compounds |
US5458631A (en) * | 1989-01-06 | 1995-10-17 | Xavier; Ravi | Implantable catheter with electrical pulse nerve stimulators and drug delivery system |
US5002053A (en) * | 1989-04-21 | 1991-03-26 | University Of Arkansas | Method of and device for inducing locomotion by electrical stimulation of the spinal cord |
US5119832A (en) * | 1989-07-11 | 1992-06-09 | Ravi Xavier | Epidural catheter with nerve stimulators |
US5031618A (en) * | 1990-03-07 | 1991-07-16 | Medtronic, Inc. | Position-responsive neuro stimulator |
US5293879A (en) * | 1991-09-23 | 1994-03-15 | Vitatron Medical, B.V. | System an method for detecting tremors such as those which result from parkinson's disease |
US5697975A (en) * | 1994-02-09 | 1997-12-16 | The University Of Iowa Research Foundation | Human cerebral cortex neural prosthetic for tinnitus |
US5527344A (en) * | 1994-08-01 | 1996-06-18 | Illinois Institute Of Technology | Pharmacologic atrial defibrillator and method |
US5662689A (en) * | 1995-09-08 | 1997-09-02 | Medtronic, Inc. | Method and apparatus for alleviating cardioversion shock pain |
US5683422A (en) * | 1996-04-25 | 1997-11-04 | Medtronic, Inc. | Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation |
US6094598A (en) * | 1996-04-25 | 2000-07-25 | Medtronics, Inc. | Method of treating movement disorders by brain stimulation and drug infusion |
US5716377A (en) * | 1996-04-25 | 1998-02-10 | Medtronic, Inc. | Method of treating movement disorders by brain stimulation |
US5707396A (en) * | 1996-04-25 | 1998-01-13 | Institute National De La Sante De La Recherche Medicale (Inserm) | Method of arresting degeneration of the substantia nigra by high frequency stimulation of subthalamic nucleus |
US5711316A (en) * | 1996-04-30 | 1998-01-27 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
US5713923A (en) * | 1996-05-13 | 1998-02-03 | Medtronic, Inc. | Techniques for treating epilepsy by brain stimulation and drug infusion |
US5782798A (en) * | 1996-06-26 | 1998-07-21 | Medtronic, Inc. | Techniques for treating eating disorders by brain stimulation and drug infusion |
US5800474A (en) * | 1996-11-01 | 1998-09-01 | Medtronic, Inc. | Method of controlling epilepsy by brain stimulation |
-
1996
- 1996-04-25 US US08/637,534 patent/US6094598A/en not_active Expired - Lifetime
-
1997
- 1997-04-02 AU AU24363/97A patent/AU2436397A/en not_active Abandoned
- 1997-04-02 WO PCT/US1997/005522 patent/WO1997039797A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4146029A (en) * | 1974-04-23 | 1979-03-27 | Ellinwood Jr Everett H | Self-powered implanted programmable medication system and method |
WO1985001213A1 (en) * | 1983-09-14 | 1985-03-28 | Jacob Zabara | Neurocybernetic prosthesis |
WO1991001756A1 (en) * | 1989-08-11 | 1991-02-21 | Skolnick Malcolm H | Method for chemical promotion of the effects of low current transcranial electrostimulation |
US5081990A (en) * | 1990-05-11 | 1992-01-21 | New York University | Catheter for spinal epidural injection of drugs and measurement of evoked potentials |
US5058584A (en) * | 1990-08-30 | 1991-10-22 | Medtronic, Inc. | Method and apparatus for epidural burst stimulation for angina pectoris |
WO1992007605A1 (en) * | 1990-11-05 | 1992-05-14 | Ravi Xavier | Implantable drug dispensing multielectrode catheter |
US5423877A (en) * | 1992-05-04 | 1995-06-13 | David C. Mackey | Method and device for acute pain management by simultaneous spinal cord electrical stimulation and drug infusion |
DE19509609A1 (en) * | 1994-04-25 | 1995-10-26 | Siemens Elema Ab | Medical device |
Cited By (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6094598A (en) * | 1996-04-25 | 2000-07-25 | Medtronics, Inc. | Method of treating movement disorders by brain stimulation and drug infusion |
US8762065B2 (en) | 1998-08-05 | 2014-06-24 | Cyberonics, Inc. | Closed-loop feedback-driven neuromodulation |
US9375573B2 (en) | 1998-08-05 | 2016-06-28 | Cyberonics, Inc. | Systems and methods for monitoring a patient's neurological disease state |
US9421373B2 (en) | 1998-08-05 | 2016-08-23 | Cyberonics, Inc. | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US9415222B2 (en) | 1998-08-05 | 2016-08-16 | Cyberonics, Inc. | Monitoring an epilepsy disease state with a supervisory module |
US9320900B2 (en) | 1998-08-05 | 2016-04-26 | Cyberonics, Inc. | Methods and systems for determining subject-specific parameters for a neuromodulation therapy |
EP1102607A2 (en) * | 1998-08-05 | 2001-05-30 | Daniel J. Dilorenzo | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US9113801B2 (en) | 1998-08-05 | 2015-08-25 | Cyberonics, Inc. | Methods and systems for continuous EEG monitoring |
US9042988B2 (en) | 1998-08-05 | 2015-05-26 | Cyberonics, Inc. | Closed-loop vagus nerve stimulation |
EP1102607A4 (en) * | 1998-08-05 | 2003-01-02 | Daniel J Dilorenzo | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US8781597B2 (en) | 1998-08-05 | 2014-07-15 | Cyberonics, Inc. | Systems for monitoring a patient's neurological disease state |
US7747325B2 (en) | 1998-08-05 | 2010-06-29 | Neurovista Corporation | Systems and methods for monitoring a patient's neurological disease state |
US7853329B2 (en) | 1998-08-05 | 2010-12-14 | Neurovista Corporation | Monitoring efficacy of neural modulation therapy |
US7930035B2 (en) | 1998-08-05 | 2011-04-19 | Neurovista Corporation | Providing output indicative of subject's disease state |
EP1048319A3 (en) * | 1999-04-30 | 2003-07-09 | Medtronic, Inc. | System for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve |
US7442183B2 (en) | 1999-04-30 | 2008-10-28 | Medtronic, Inc. | Techniques for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve |
US7588581B2 (en) | 2002-03-26 | 2009-09-15 | Medtronic, Inc. | Placement of chronic micro-catheter device and method |
US7160913B2 (en) | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
US7107104B2 (en) | 2003-05-30 | 2006-09-12 | Medtronic, Inc. | Implantable cortical neural lead and method |
US9760688B2 (en) | 2004-07-07 | 2017-09-12 | Cleveland Clinic Foundation | Method and device for displaying predicted volume of influence |
US11452871B2 (en) | 2004-07-07 | 2022-09-27 | Cleveland Clinic Foundation | Method and device for displaying predicted volume of influence |
US10322285B2 (en) | 2004-07-07 | 2019-06-18 | Cleveland Clinic Foundation | Method and device for displaying predicted volume of influence |
US9339650B2 (en) | 2005-04-13 | 2016-05-17 | The Cleveland Clinic Foundation | Systems and methods for neuromodulation using pre-recorded waveforms |
US9211408B2 (en) | 2005-04-13 | 2015-12-15 | The Cleveland Clinic Foundation | System and method for neuromodulation using composite patterns of stimulation or waveforms |
US8112154B2 (en) | 2005-04-13 | 2012-02-07 | The Cleveland Clinic Foundation | Systems and methods for neuromodulation using pre-recorded waveforms |
US10360511B2 (en) | 2005-11-28 | 2019-07-23 | The Cleveland Clinic Foundation | System and method to estimate region of tissue activation |
US8725243B2 (en) | 2005-12-28 | 2014-05-13 | Cyberonics, Inc. | Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
US9592004B2 (en) | 2005-12-28 | 2017-03-14 | Cyberonics, Inc. | Methods and systems for managing epilepsy and other neurological disorders |
US9044188B2 (en) | 2005-12-28 | 2015-06-02 | Cyberonics, Inc. | Methods and systems for managing epilepsy and other neurological disorders |
US8868172B2 (en) | 2005-12-28 | 2014-10-21 | Cyberonics, Inc. | Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders |
US7676263B2 (en) | 2006-06-23 | 2010-03-09 | Neurovista Corporation | Minimally invasive system for selecting patient-specific therapy parameters |
US9480845B2 (en) | 2006-06-23 | 2016-11-01 | Cyberonics, Inc. | Nerve stimulation device with a wearable loop antenna |
US8295934B2 (en) | 2006-11-14 | 2012-10-23 | Neurovista Corporation | Systems and methods of reducing artifact in neurological stimulation systems |
US8855775B2 (en) | 2006-11-14 | 2014-10-07 | Cyberonics, Inc. | Systems and methods of reducing artifact in neurological stimulation systems |
US9622675B2 (en) | 2007-01-25 | 2017-04-18 | Cyberonics, Inc. | Communication error alerting in an epilepsy monitoring system |
US9898656B2 (en) | 2007-01-25 | 2018-02-20 | Cyberonics, Inc. | Systems and methods for identifying a contra-ictal condition in a subject |
WO2008107822A1 (en) * | 2007-03-02 | 2008-09-12 | Koninklijke Philips Electronics N.V. | Electrode system for deep brain stimulation |
US9445730B2 (en) | 2007-03-21 | 2016-09-20 | Cyberonics, Inc. | Implantable systems and methods for identifying a contra-ictal condition in a subject |
US8036736B2 (en) | 2007-03-21 | 2011-10-11 | Neuro Vista Corporation | Implantable systems and methods for identifying a contra-ictal condition in a subject |
US8543199B2 (en) | 2007-03-21 | 2013-09-24 | Cyberonics, Inc. | Implantable systems and methods for identifying a contra-ictal condition in a subject |
US9788744B2 (en) | 2007-07-27 | 2017-10-17 | Cyberonics, Inc. | Systems for monitoring brain activity and patient advisory device |
WO2009067610A1 (en) | 2007-11-20 | 2009-05-28 | The Cleveland Clinic Foundation | Systems and methods for neuromodulation using pre-recorded waveforms |
US9259591B2 (en) | 2007-12-28 | 2016-02-16 | Cyberonics, Inc. | Housing for an implantable medical device |
US11406317B2 (en) | 2007-12-28 | 2022-08-09 | Livanova Usa, Inc. | Method for detecting neurological and clinical manifestations of a seizure |
US10434302B2 (en) | 2008-02-11 | 2019-10-08 | Intelect Medical, Inc. | Directional electrode devices with locating features |
US9545510B2 (en) | 2008-02-12 | 2017-01-17 | Intelect Medical, Inc. | Directional lead assembly with electrode anchoring prongs |
US9526902B2 (en) | 2008-05-15 | 2016-12-27 | Boston Scientific Neuromodulation Corporation | VOA generation system and method using a fiber specific analysis |
US8849390B2 (en) | 2008-12-29 | 2014-09-30 | Cyberonics, Inc. | Processing for multi-channel signals |
US9289595B2 (en) | 2009-01-09 | 2016-03-22 | Cyberonics, Inc. | Medical lead termination sleeve for implantable medical devices |
US8588933B2 (en) | 2009-01-09 | 2013-11-19 | Cyberonics, Inc. | Medical lead termination sleeve for implantable medical devices |
US8786624B2 (en) | 2009-06-02 | 2014-07-22 | Cyberonics, Inc. | Processing for multi-channel signals |
US10981013B2 (en) | 2009-08-27 | 2021-04-20 | The Cleveland Clinic Foundation | System and method to estimate region of tissue activation |
US11944821B2 (en) | 2009-08-27 | 2024-04-02 | The Cleveland Clinic Foundation | System and method to estimate region of tissue activation |
US9776003B2 (en) | 2009-12-02 | 2017-10-03 | The Cleveland Clinic Foundation | Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming |
US9643019B2 (en) | 2010-02-12 | 2017-05-09 | Cyberonics, Inc. | Neurological monitoring and alerts |
US9867989B2 (en) | 2010-06-14 | 2018-01-16 | Boston Scientific Neuromodulation Corporation | Programming interface for spinal cord neuromodulation |
US9501829B2 (en) | 2011-03-29 | 2016-11-22 | Boston Scientific Neuromodulation Corporation | System and method for atlas registration |
US9592389B2 (en) | 2011-05-27 | 2017-03-14 | Boston Scientific Neuromodulation Corporation | Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information |
US9925382B2 (en) | 2011-08-09 | 2018-03-27 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related volume analysis, creation, and sharing |
US9604067B2 (en) | 2012-08-04 | 2017-03-28 | Boston Scientific Neuromodulation Corporation | Techniques and methods for storing and transferring registration, atlas, and lead information between medical devices |
US11633608B2 (en) | 2012-08-28 | 2023-04-25 | Boston Scientific Neuromodulation Corporation | Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines |
US10946201B2 (en) | 2012-08-28 | 2021-03-16 | Boston Scientific Neuromodulation Corporation | Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines |
US9643017B2 (en) | 2012-08-28 | 2017-05-09 | Boston Scientific Neuromodulation Corporation | Capture and visualization of clinical effects data in relation to a lead and/or locus of stimulation |
US10016610B2 (en) | 2012-08-28 | 2018-07-10 | Boston Scientific Neuromodulation Corporation | Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines |
US10265532B2 (en) | 2012-08-28 | 2019-04-23 | Boston Scientific Neuromodulation Corporation | Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines |
US9561380B2 (en) | 2012-08-28 | 2017-02-07 | Boston Scientific Neuromodulation Corporation | Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines |
US9821167B2 (en) | 2012-08-28 | 2017-11-21 | Boston Scientific Neuromodulation Corporation | Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines |
US11938328B2 (en) | 2012-08-28 | 2024-03-26 | Boston Scientific Neuromodulation Corporation | Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines |
US11923093B2 (en) | 2012-11-01 | 2024-03-05 | Boston Scientific Neuromodulation Corporation | Systems and methods for VOA model generation and use |
US9959940B2 (en) | 2012-11-01 | 2018-05-01 | Boston Scientific Neuromodulation Corporation | Systems and methods for VOA model generation and use |
US9792412B2 (en) | 2012-11-01 | 2017-10-17 | Boston Scientific Neuromodulation Corporation | Systems and methods for VOA model generation and use |
US9959388B2 (en) | 2014-07-24 | 2018-05-01 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for providing electrical stimulation therapy feedback |
US10265528B2 (en) | 2014-07-30 | 2019-04-23 | Boston Scientific Neuromodulation Corporation | Systems and methods for electrical stimulation-related patient population volume analysis and use |
US11806534B2 (en) | 2014-07-30 | 2023-11-07 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related biological circuit element analysis and use |
US11602635B2 (en) | 2014-07-30 | 2023-03-14 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related volume analysis of therapeutic effects and other clinical indications |
US10272247B2 (en) | 2014-07-30 | 2019-04-30 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming |
US10357657B2 (en) | 2014-10-07 | 2019-07-23 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters |
US11202913B2 (en) | 2014-10-07 | 2021-12-21 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters |
US9974959B2 (en) | 2014-10-07 | 2018-05-22 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters |
US9956419B2 (en) | 2015-05-26 | 2018-05-01 | Boston Scientific Neuromodulation Corporation | Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation |
US10780283B2 (en) | 2015-05-26 | 2020-09-22 | Boston Scientific Neuromodulation Corporation | Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation |
US10441800B2 (en) | 2015-06-29 | 2019-10-15 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting stimulation parameters by targeting and steering |
US11110280B2 (en) | 2015-06-29 | 2021-09-07 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting stimulation parameters by targeting and steering |
US11160981B2 (en) | 2015-06-29 | 2021-11-02 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects |
US10071249B2 (en) | 2015-10-09 | 2018-09-11 | Boston Scientific Neuromodulation Corporation | System and methods for clinical effects mapping for directional stimulation leads |
US10716942B2 (en) | 2016-04-25 | 2020-07-21 | Boston Scientific Neuromodulation Corporation | System and methods for directional steering of electrical stimulation |
US10776456B2 (en) | 2016-06-24 | 2020-09-15 | Boston Scientific Neuromodulation Corporation | Systems and methods for visual analytics of clinical effects |
US10350404B2 (en) | 2016-09-02 | 2019-07-16 | Boston Scientific Neuromodulation Corporation | Systems and methods for visualizing and directing stimulation of neural elements |
US10780282B2 (en) | 2016-09-20 | 2020-09-22 | Boston Scientific Neuromodulation Corporation | Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters |
US11752348B2 (en) | 2016-10-14 | 2023-09-12 | Boston Scientific Neuromodulation Corporation | Systems and methods for closed-loop determination of stimulation parameter settings for an electrical simulation system |
US10603498B2 (en) | 2016-10-14 | 2020-03-31 | Boston Scientific Neuromodulation Corporation | Systems and methods for closed-loop determination of stimulation parameter settings for an electrical simulation system |
US10792501B2 (en) | 2017-01-03 | 2020-10-06 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting MRI-compatible stimulation parameters |
US10589104B2 (en) | 2017-01-10 | 2020-03-17 | Boston Scientific Neuromodulation Corporation | Systems and methods for creating stimulation programs based on user-defined areas or volumes |
US10625082B2 (en) | 2017-03-15 | 2020-04-21 | Boston Scientific Neuromodulation Corporation | Visualization of deep brain stimulation efficacy |
US11357986B2 (en) | 2017-04-03 | 2022-06-14 | Boston Scientific Neuromodulation Corporation | Systems and methods for estimating a volume of activation using a compressed database of threshold values |
US10716505B2 (en) | 2017-07-14 | 2020-07-21 | Boston Scientific Neuromodulation Corporation | Systems and methods for estimating clinical effects of electrical stimulation |
US10960214B2 (en) | 2017-08-15 | 2021-03-30 | Boston Scientific Neuromodulation Corporation | Systems and methods for controlling electrical stimulation using multiple stimulation fields |
US11298553B2 (en) | 2018-04-27 | 2022-04-12 | Boston Scientific Neuromodulation Corporation | Multi-mode electrical stimulation systems and methods of making and using |
US11285329B2 (en) | 2018-04-27 | 2022-03-29 | Boston Scientific Neuromodulation Corporation | Systems and methods for visualizing and programming electrical stimulation |
US11583684B2 (en) | 2018-04-27 | 2023-02-21 | Boston Scientific Neuromodulation Corporation | Systems and methods for visualizing and programming electrical stimulation |
US11944823B2 (en) | 2018-04-27 | 2024-04-02 | Boston Scientific Neuromodulation Corporation | Multi-mode electrical stimulation systems and methods of making and using |
Also Published As
Publication number | Publication date |
---|---|
US6094598A (en) | 2000-07-25 |
AU2436397A (en) | 1997-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6094598A (en) | Method of treating movement disorders by brain stimulation and drug infusion | |
EP0959942B1 (en) | Apparatus for treating movement disorders by closed loop brain stimulation | |
US6227203B1 (en) | Techniques for controlling abnormal involuntary movements by brain stimulation and drug infusion | |
US6356784B1 (en) | Method of treating movement disorders by electrical stimulation and/or drug infusion of the pendunulopontine nucleus | |
US5978702A (en) | Techniques of treating epilepsy by brain stimulation and drug infusion | |
US6263237B1 (en) | Techniques for treating anxiety disorders by brain stimulation and drug infusion | |
US6109269A (en) | Method of treating addiction by brain infusion | |
US6353762B1 (en) | Techniques for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve | |
DE69731947T2 (en) | APPARATUS FOR TREATING MOTION FLUCTURES BY INTRACEREBRAL TO BE INFLUENCED | |
US6176242B1 (en) | Method of treating manic depression by brain infusion | |
US5683422A (en) | Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation | |
US5975085A (en) | Method of treating schizophrenia by brain stimulation and drug infusion | |
US5814014A (en) | Techniques of treating neurodegenerative disorders by brain infusion | |
US5782798A (en) | Techniques for treating eating disorders by brain stimulation and drug infusion | |
US8401634B2 (en) | Treatment of movement disorders by brain stimulation | |
EP1014881B1 (en) | System for treating neurodegenerative disorders by infusion of nerve growth factors into the brain | |
AU744851B2 (en) | Implantable seizure warning system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97538085 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |